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V Summary 
Idiopathic pulmonary fibrosis (IPF) is the most common and most severe form of the 
idiopathic interstitial pneumonias (IIP). Unresponsive to any currently available therapy it 
leads to architectural distortion of the lung parenchyma and rapidly to respiratory failure. 
Although the pathogenesis of the disease is not completely understood, it is well accepted that 
initial alveolar epithelial cell injury is followed by enhanced fibroblast proliferation and 
activation to myofibroblasts. These fibroblasts are considered as key effector cells in IPF. The 
so called fibroblast foci represent hallmark lesions of the disease as they are responsible for 
the increased ECM deposition that leads to impaired gas exchange and ultimately to fibrosis. 
The present study aimed to reveal possible profibrotic paracrine effects of recently identified 
profibrotic mediators that trigger the disturbed crosstalk between alveolar epithelial cells type 
II (ATII) and fibroblasts. Recently, WNT/β-catenin signaling has been demonstrated to be 
involved in the pathogenesis of IPF. In particular it has been reported that WNT3a and 
WNT1-inducible signaling protein (WISP) 1 are secreted by ATII cells in IPF.  
In the present project it was hypothesized that WNT3a and WISP1 act in a paracrine fashion 
on fibroblasts, thereby contributing to the impaired ATII cell ̶ fibroblast crosstalk in the 
pathogenesis of IPF. 
It was shown that active WNT/β-catenin signaling takes place in NIH-3T3 fibroblasts in vitro 
as assessed by Western Blot analysis and quantitative RT-PCR. To reveal functional effects of 
active WNT/β-catenin signaling, thymidine [H3] incorporation proliferation assay, 
immunofluorescence, Sircol Collagen Assay, as well as quantitative (q) RT-PCR were 
performed.  
WNT3a stimulation of fibroblasts caused a significantly increased production of the 
extracellular matrix component collagen and led to transcriptional upregulation of fibroblast 
activation markers. Interestingly, WNT3a stimulation did not affect fibroblast proliferation. 
The paracrine effects of WISP-1, which is encoded by a WNT target gene, were analyzed in a 
comparable way. Like WNT3a, WISP-1 led to enhanced collagen deposition as well as 
upregulation of fibroblast activation markers. Proliferation of the fibroblasts remained 
unaffected. 
These results provided evidence that both molecules, WNT3a and WISP1, are capable of 
activating lung fibroblasts and causing increased collagen production in these cells. Therefore 
it is strongly suggested that WNT3a and WISP-1, which are aberrantly secreted by ATII cells 
in IPF, are profibrotic mediators that act in a paracrine fashion on fibroblasts during the 
pathogenesis of this fatal disease. 
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VI Zusammenfassung 
Die idiopathische pulmonale Fibrose (IPF) ist die häufigste und schwerwiegendste Form der 
idiopathische interstitiellen Pneumonien (IIP). Sie ist therapierefraktär, führt zu Zerstörung 
der Architektur des Lungenparenchyms und rasch zu respiratorischem Versagen.  
Die Pathogenese der Erkrankung ist größtenteils ungeklärt, wobei neue Studien eine initiale 
Schädigung von Alveolarepithelzellen (AT) vermuten lassen, woraufhin es zu gesteigerter 
Fibroblastenproliferation und Aktivierung von Fibroblasten in so genannten Fibroblasten Foci 
kommt. Diese Foci sind für die gesteigerte Produktion extrazellulärer Matrix verantwortlich, 
welche zum fibrotischen Umbau des Gewebes führt.  
Das Ziel der vorliegenden Studie war es, mögliche Effekte bereits identifizierter 
profibrotischer Mediatoren zu untersuchen, die die Kommunikation zwischen AT II Zellen 
und Fibroblasten stören. 
Kürzlich konnte gezeigt werden, dass der WNT/β-catenin Signalweg in der Pathogenese der 
IPF eine Rolle spielt. Insbesondere wurde gezeigt, dass WNT3a sowie das WNT1-inducible 
signaling protein-1 (WISP-1) im Rahmen der IPF von ATII Zellen sezerniert werden.  
Für das hier vorgestellte Projekt wurde die Hypothese aufgestellt, dass WNT3a und WISP1 
parakrin auf Fibroblasten wirken und somit zur gestörten Kommunikation zwischen ATII- 
Zellen und Fibroblasten im Rahmen der Pathogenese von IPF beitragen. 
Mittels Western Blot Analyse und quantitativer RT-PCR konnte gezeigt werden, dass der 
WNT/β-catenin Signalweg in NIH-3T3 Fibroblasten in vitro aktiviert werden kann. Weitere 
Effekte einer Aktivierung des WNT/β-catenin Signalwegs wurden mittels Thymidin [H3] 
Proliferations Assay, Immunfluoreszenz, Sircol Collagen Assay und quantitativer RT-PCR 
durchgeführt. 
WNT3a führte zu einer deutlich erhöhten Kollagenproduktion. Zudem kam es zu einer 
erhöhten Transkription von typischen Markern einer Fibroblastenaktivierung. 
Interessanterweise beeinflusste WNT3a die Fibroblastenproliferation nicht. Die parakrinen 
Effekte von WISP-1, welches von einem WNT Targetgen kodiert wird, wurden ebenfalls 
untersucht. Vergleichbar mit WNT3a führte WISP-1 zu einer erhöhten Kollagenbildung und 
Fibroblastenaktivierung. Die Proliferationsrate der Fibroblasten änderte sich hingegen nicht. 
Die vorliegenden Ergebnisse zeigen, dass beide Proteine, WNT3a und WISP-1, zu einer 
Aktivierung sowie einer erhöhten Kollagenproduktion von Lungenfibroblasten führen 
können. WNT3a und WISP-1, welche in IPF verstärkt von ATII Zellen sezerniert werden, 
wirken parakrin auf Fibroblasten und stellen somit bedeutende profibrotische Mediatoren in 
der Pathogenese der IPF dar.  
. 
1. Introduction 1 
1. Introduction 
1.1 Interstitial lung diseases 
Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases (DPLDs) are a 
heterogenous group of chronical disorders that mainly affect the interstitium of the lung 
containing the space between the basement membranes of the alveolar epithelium and the 
capillary endothelium 1. Common feature of these diseases is an increase of connective tissue 
that ultimately leads to fibrosis accompanied by reduced lung compliance and impaired gas 
exchange. Without an appropriate therapy this process results in cor pulmonale and 
respiratory failure 2. The ILDs are divided into two groups: 1) disorders that occur secondary 
to a known cause, and 2) disorders that lack an obvious origin. Known causes for ILD are 
infections, inhalation of anorganic and organic dusts, and circulation disorders. They occur 
also in association to systemical diseases, like sarcoidosis or collagen vascular diseases. The 
second group includes all cases with an idiopathic entity, such as the rare pulmonary 
histiocytosis x (HX), lymphangioleiomyomatosis (LAM), eosinophilic pneumonia and the 
more frequent idiopathic interstitial pneumonias (IIPs) 1,3.  
The IIPs include seven entities that can be mainly distinguished by histologic and radiologic 
patterns as well as clinical features: idiopathic pulmonary fibrosis (IPF), nonspecific 
interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), acute interstitial 
pneumonia (AIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), 
desquamantative interstitial pneumonia (DIP), and lymphocytic interstitial pneumonia (LIP) 1 
 
 
 
Figure 1. Scheme of DPLD classification 
1
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1.2 Idiopathic pulmonary fibrosis 
1.2.1 Epidemiology  
Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis (CFA), 
represents the most common form of the IIPs 4. It mostly occurs in 50 - 70 year old patients 
with an incidence of 7 – 10 cases per 100.000 and is more common in men 5,6. Unresponsive 
to any currently available therapy, with a median survival time of 2.5 – 3.5 years, it is also 
considered as the most aggressive form with the worst prognosis of the seven entities 1,7-9. The 
following figure shows the worse survival in IPF patients compared to NSIP and other 
ILDs 10. 
                            
 
Figure 2. Survival of IPF/UIP patients compared to SIP and other DPLD 
In comparison to NSIP and other DPLDs IPF exhibits the worst prognosis with a median survival about 3 
years 10. 
 
1.2.2 Clinical and histopathological features  
The patient usually shows dyspnoea and non productive cough. On auscultation often Velcro-
type inspiratory crackles are audible over the basal areas of the lung. Digital clubbing can be 
observed frequently 1,6,7. Radiological characteristics are reticular opacities and 
honeycombing that mainly affect the peripheral, basal and subpleural parts of the lung 1,4. 
Lung function test mostly depicts a restrictive pattern with reduced lung compliance and 
impaired gas exchange that in the course of the disease leads to decrease of the physical 
capacity and loss of life quality. In the late stages the patient develops a cor pulmonale. 
Respiratory failure is the most common reason for lethal outcome of the disorder 1,2,11. 
Because of its devastating character and its lack of effective medicamentous therapy, it is 
important to differentiate between IPF and the other IIPs 1,12. Table 1 shows diagnostic  
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criteria for IPF, determined by the ATS consensus of 2002, which have to be considered when 
no surgical lung biopsy is available 1. A correct clinical diagnosis of IPF is probable in 
presence of all major as well as at least three of the four minor diagnostic criteria in the 
immunocompetent adult 1. 
 
Major Criteria  
 
• Exclusion of other known causes of ILD such as certain drug toxicities, 
environmental exposures, and connective tissue diseases 
 
• Abnormal pulmonary function studies that include evidence of restriction 
(reduced VC, often with an increased FEV1/FVC ratio) and impaired gas 
exchange [increased P(A–a)O2, decreased PaO2 with rest or exercise or 
decreased DLCO] 
 
• Bibasilar reticular abnormalities with minimal ground glass opacities on 
HRCT scans 
 
• Transbronchial lung biopsy or BAL showing no features to support an 
alternative diagnosis 
Minor Criteria 
 
• Age > 50 yr 
 
• Insidious onset of otherwise unexplained dyspnoea on exertion 
 
• Duration of illness > 3 mo 
 
• Bibasilar, inspiratory crackles (dry or “Velcro”-type in quality) 
 
Table 1. ATS/ERS Criteria for diagnosis of IPF in absence of surgical lung biopsy 
1
. 
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To confirm the diagnosis IPF histologically, it is important to get a surgical lung biopsy. The 
corresponding histologic pattern is called usual interstitial pneumonia (UIP) and sometimes 
used synonymously to the term IPF 1.  
 
Key Histologic Features 
 
• Dense fibrosis causing remodeling of lung architecture with frequent 
“honeycomb” fibrosis 
• Fibroblastic foci typically scattered at the edges of dense scars 
• Patchy lung involvement 
• Frequent subpleural and paraseptal distribution 
 
Pertinent Negative Findings 
 
• Lack of active lesions of other interstitial diseases (i.e., sarcoidosis or 
Langerhans’ cell histiocytosis) 
• Lack of marked interstitial chronic inflammation 
• Granulomas: inconspicuous or absent 
• Lack of substantial inorganic dust deposits, i.e., asbestos bodies (except for 
carbon black pigment) 
• Lack of marked eosinophilia 
 
Table 2. Histologic features of Usual interstitial pneumonia (UIP) 
1
. 
 
Architectural distortion of the lung parenchyma as an obligatory consequence of the disorder 
is marked by fibrosis that consists of dense interstitial extracellular matrix (ECM) alternating 
with cystically dilatated bronchioli, the so called honeycomb cysts. Another characteristic 
lesion are aggregates of activated myofibroblasts, also referred to as fibroblast foci 4,13,5 The 
prognostic value of fibroblast foci during IPF pathogenesis is controversially discussed. Some 
authors did not find an association between an increased number of fibroblast foci and a 
worse prognosis 14. However, other studies report an inverse correlation between the number 
of fibroblast foci and the survival of the patient 15,16. According to these reports, an increasing 
number of fibroblast foci correlates to an impairment of lung function. Therefore, the number  
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of fibroblast foci can be considered as an important factor that enables indicating the 
individual prognosis of the patient 15,16. 
 
A.      B. 
 
 
 
 
 
 
 
 
 
C.      D. 
 
 
 
 
 
 
 
 
 
Figure 3. Histopathological changes in IPF. 
(A) Structures of a healthy lung (magnification 10×). (B) Structures of an IPF lung (magnification 10×). (C) 
Fibroblast focus in an IPF lung. The fibroblast focus is indicated with arrow (magnification 40×). Tissue sections 
were stained for smooth muscle actin, and with hematoxylin and eosin. (D) Honeycomb cystic changes in an IPF 
lung 17.  
 
1.2.3 Pathomechanisms of idiopathic pulmonary fibrosis 
Despite a lot of research efforts, the initial cause and the pathogenic mechanisms of IPF 
remain enigmatic 18. The (myo-) fibroblast foci and increased interstitial ECM deposition are 
currently regarded as a consequence of proliferation and activation of fibroblasts, which is 
initiated by chronic alveolar epithelial cell damage 4. In the other 6 forms of IIPs the role of 
inflammation as the preceding trigger for the development of pulmonary fibrosis is more 
emphasized 7. 
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A. Current hypothesis in IPF pathogenesis: epithelial injury as the initial trigger  
For a long time most forms of pulmonary fibrosis were regarded as a predominant  
inflammatory response to an unknown stimulus 5,18. In this concept enhanced ECM deposition 
and fibrosis are caused by inflammatory cells, cytokines, and growth factors in order to repair 
the affected tissue 19. In IPF, this hypothesis has been challenged. This is mainly due to 
several observations: 1) anti-inflammatory drugs do not lead to the expected therapeutic 
success, and 2) IPF patients´ histology does not exhibit high, but rather mild to moderate 
degrees of inflammation at different stages of the disease 7,12,18 . Thus, the current suggestion 
of IPF pathogenesis abandons the emphasis of inflammation and claims repetitive epithelial 
microinjuries and subsequent cell death next to hyperplastic and inappropriate repair 
processes as key pathogenic mechanisms in the development of the disease. Consequences are 
disruption of the epithelial integrity in the alveoli lacking the ability to re-epithelialize, and 
the release of profibrotic cytokines and growth factors by the damaged epithelial cells. 
Migration and accumulation of fibroblasts occur subsequently and further on generate 
enhanced ECM deposition 7,12. However, the “inflammatory” concept should not be excluded 
from the pathogenesis, but rather included as an associating factor into the more prominent 
force: the alveolar epithelial injury 2,12.  
 
B. Fibroblasts in IPF pathogenesis: key effector cells 
As members of the connective tissue cell family, fibroblasts are mesenchymal derived cells. 
They occur in every tissue, where they can be activated to synthesize and secrete components 
of the ECM that consists of collagens, elastins, and proteoglycans. In the lung, fibroblasts 
play a crucial role for maintaining normal lung function, ventilation, and gas exchange 20,21. 
By providing an organ with ECM as a tissue scaffold during repair processes, fibroblasts are 
pivotal for tissue remodelling and wound healing processes 22. Contributing to that function, 
they additionally posses the ability to secrete growth factors, cytokines, express integrins or 
release oxidants, thereby being able to influence other cell types´ proliferation, migration, and 
apoptosis 23. Fibroblasts do not appear in a fixed phenotype. Depending on the circumstances 
and requirements of their surroundings, they can change their phenotype and appear as a 
migratory, proliferative phenotype or as profibrotic, activated phenotypes 24.  
In IPF pathogenesis, fibroblasts can be regarded as key effector cells. They are responsible for 
the impaired physiological balance of ECM deposition that finally leads to destruction of  
normal lung architecture and accumulation of fibrotic scar tissue. Fibroblast foci represent  
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hallmark lesions of the disease. They comprise myofibroblasts that constitute a synthetically 
active contractile phenotype and secrete an overabundance of ECM components 13,25,26,27, 
which also occurs in skin wound healing processes 22. The fact that they are localized in the  
subepithelial layer in close proximity to injured alveolar epithelium underlines the assumption 
that an impaired crosstalk between both cell types mediates the progression of the 
disease 13,25. It remains unclear, which mechanism initially triggers the differentiation of the 
fibroblasts, but a possible role of local growth factors and cytokines is well accepted 8,28. 
Source of these profibrotic molecules are probably hyperplastic alveolar epithelial cells type 
II (ATII), which release growth factors and cytokines 7,12 that can influence phenotype and 
behaviour of fibroblasts in a paracrine fashion. Identification of such possibly profibrotic 
mediators and analysis of their effects could provide new information about pathogenic 
mechanisms in IPF, including crosstalks to signaling pathways that are already known to be  
involved in the progression of the disease. Thereby, new therapeutical options targeting these 
mediators may be developed.  
 
 
 
 
 
Figure 4. Hypothetical scheme of the primary pathogenic events in IPF 
12
. 
Alveolar epithelial cells are activated by unknown injuries and release factors that influence phenotype and 
behaviour of fibroblasts. In the lesion, myofibroblasts can induce epithelial cell apoptosis and disruption of 
basement membrane contributing to abnormal re-epithelialization. Additionally, activated fibroblasts secrete 
excessive amounts of ECM 12. 
 
 
 
Fibroblast activation 
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1.3 WT signaling  
1.3.1 WT family of signaling molecules – classification and physiology 
The WNT family of signaling molecules consists of secreted glycoproteins that play an 
important role as ligands in receptor mediated signaling pathways. The name WNT is 
composed of two homologous genes:  Wingless (Wg), a segment polarity gene from  
Drosophila and Int1, a proto-oncogene associated with mammary tumors 29,30. 
In mammals, 19 WNT members are known, encoded by Wnt genes. Names of gene and 
corresponding protein are the same: WNT 1, 2, 2b, 3, 3a, 4, 5a, 5b, 6, 7a, 7b, 8a, 8b, 9a, 9b, 
10a, 10b, 11 and 16 I. The proteins, in length of usually 350-400 amino acids (aa), have a 
highly conserved sequence that is characterized by a signal domain and a cysteine pattern 31,32. 
Before they are secreted, WNT ligands undergo posttranslational modifications, such as 
glycosylation and palmitoylation. In palmitoylated form, the ligands, like the representative 
WNT3a, transduce signals into the cytoplasm of different target cells 33,34. Signal transduction 
in the cytoplasm of different target cells leads to changed expression of various target genes 
and subsequently can influence proliferation, migration, differentiation and cell fate 
specification. Active WNT signal transduction is a key process during development and is 
also described in cancer 35,36. Currently, three different pathways are known, which describe 
the downstream signaling of WNT binding to the cell surface. The first and best understood 
pathway is the β-catenin dependent canonical WNT pathway (WNT/β-catenin pathway). The 
second involves Ca2+ and further one is associated with the c-Jun N-terminal kinase (JNK). 
The latter one is also related to as the Planar Cell Polarity Pathway (PCP) 31,35-38.  
 
1.3.2 The WT/β-catenin signaling pathway 
WNT/β-catenin signaling, also referred to as canonical WNT signaling, involves the 
transcriptional regulator β-catenin as an intracellular key molecule. Known ligands that 
induce this pathway are: WNT 1, 2, 2b, 3, 3a, 7a, 7b, 8, 10. In absence of WNT, the 
intracellular β-catenin level is low, because the molecule is destined to proteasome-mediated 
degradation by a so-called degradation complex. This complex is composed of Axin, 
adenomatous polyposis coli (APC) and glycogen synthase kinase- (GSK) 3β. GSK3β together 
with casein kinase γ (CK γ ) is responsible for constitutive phosphorylation of β-catenin that  
in this form is targeted for ubiquitination and afterwards degradation 31,35. When WNT/β-
catenin signaling is activated, this degradation pathway is inhibited. In this case, WNT ligands  
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bind to the seven transmembrane receptors Frizzled (FZD) that form the primary receptors at 
the cell membrane 39. The following Fzd receptors are already known to interact with WNT 
and activate the signaling cascade: Fzd 1, 2, 3, 4, 5, 7, 8 and 9 I. WNTs bind to an 
extracellular cysteine rich domain of one of these receptors that builds a complex with a 
single pass transmembrane coreceptor. This coreceptor, in Drosophila encoded by the gene 
arrow, is called low density lipoprotein receptor-related protein (LRP) 5 or 6 40. After ligand  
binding to the receptors the signal is transduced to Dishevelled (DSH), another intracellular 
pathway component with the ability to interact with Axin. Axin is recruited by DSH and binds 
directly to the cytoplasmatic tail of LRP5/6 41. Without Axin the degradation complex is 
inhibited and β-catenin is not phosphorylated anymore. Subsequently, hypophosphorylated β-
catenin accumulates in the cytoplasm and is translocated to the nucleus. There it replaces the 
repressing factor Groucho from transcription factors of the T-cell-specific transcription 
factor/lymphoid enhancer-binding factor (TCF/LEF) family and thereby activates the 
transcription of WNT target genes 31,35,42. Effects of WNT/β-catenin signaling differ cell-type 
specific. Hence, the target cell determines the response 35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Overview of canonical WT signaling pathway 
36
. 
Degradation of cytosolic β-catenin in absence of WNT(left). Signaling cascade in presence of WNT ligand at the 
cell surface (right). 
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According to the fact that different cell types or tissues respond in distinct manners to WNT 
binding, ligand-receptor affinity varies depending not only on the particular WNT ligand and 
FZD receptor, but also on the cell type 35.  
Extensive research, mostly via microarray analysis, has led to the identification of numerous 
direct and indirect WNT target genes. One group of WNT-inducible genes are components of 
the pathway themselves, indicating a feedback control 35,I. Other target genes, such as the cell  
cycle regulators myc 43 and Cyclin D1 (CycD1) 44,45 or the matrix metalloproteinase 7 (Mmp7) 
/matrilysin 46 are listed on the WNT Homepage. They point the functional relevance of WNT 
signaling in different organs, tissues and cells. Mutations or other defects causing disturbed or 
constitutively active signal transduction can result in developmental abnormalities or 
diseases 35. 
 
1.3.2.1 WT/β-catenin signaling in diseases 
The fundamental importance of WNT signaling during development and for balanced tissue 
maintenance is reflected in diseases occurring in association to mis-regulated signaling. Most 
of them were firstly identified by mutant phenotype analysis in mice, but actually numerous 
human diseases can be correlated to disturbed WNT/β-catenin signaling. 
Currently, the most frequent and therefore best studied issue is the relation of WNT signaling 
to cancer. As many WNT target genes are involved in proliferation, apoptosis, and cell cycle 
regulation – functions that are out of order during tumorigenesis – a contribution of the 
canonical pathway to these processes suggests itself 47. Mutations in Axin, part of the 
degradation complex result in increased canonical signaling and were found in colon cancer 
as well as hepatocellular carcinoma 48,49. Constitutive activation of the pathway can also be 
caused by truncation of APC or mutations in β-catenin and are reported to induce colon 
cancer and familial adenomatous polyposis (FAP), a hereditary disorder characterized by 
precancerous polyps 50. Involvement of WNT signaling in pancreatic, ovarian, prostate and 
mammary cancer has been also reported 50. In lung cancer it was shown that overexpression 
of WNT1 and some of its target genes is associated with tumor progression and impairment of 
the prognosis 51,52. Also, it was already suggested that a WNT inhibitory factor has the 
capacity to arrest cell growth in lung cancer 53.  
Wound healing and skin represent other areas, in which the role of canonical signal  
transduction is examined. Active WNT/β-catenin signaling is involved in the recruitment of  
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fibroblasts and influences their behaviour, thereby playing a role in fibromatosis and wound 
healing in general 54,55. Furthermore it contributes to the development of fibrotic diseases that 
are characterized by pathologic tissue remodelling 56-58: 
In experimental liver fibrosis the expression of WNT and FZD was demonstrated. 
Additionally, WNT antagonism was able to inhibit activation of hepatic stellate cells that 
represents one of the main pathologic events in liver fibrosis 56. WNT4 and WNT/β-catenin 
signaling respectively were reported to be involved in the pathogenesis of renal fibrosis as 
well as WNT inhibition was able to affect the progression 57,58.  
 
In sum, many reports have established involvement of WNT/β-catenin signaling in cancer and 
fibrotic diseases. From this emanate possible approaches for new therapies that require further 
investigation in the field.  
 
1.3.2.2 WT/β-catenin signaling in the lung and in IPF 
The WNT/β-catenin signaling pathway plays a fundamental part in lung development. Several 
WNT proteins are expressed in the lung, in the adult organ as well as during development 35.  
In mice with deficiency of WNT5a or WNT7b various lung defects affecting both epithelium 
and mesenchymal cells could be observed at different developmental stages. Given that these 
two proteins are expressed only in the epithelium, the defects can be referred to autocrine and 
paracrine signaling mechanisms as well 59. Lack of β-catenin, the intracellular key molecule 
of canonical signaling, leads to misformation of the distal airways that are required for 
appropriate gas exchange 60. These and other observations that reflect the relevance of WNT 
in lung development indicate that it can also be involved in pathologic processes in the adult 
organ. This suggestion was followed by Chilosi and colleagues 61, who reported an increase of 
β-catenin in fibroblast foci and alveolar epithelial cells type II (ATII) indicative of an aberrant 
activation of WNT signal transduction in IPF 59. Furthermore, in our laboratory an increase of 
functional WNT signaling in IPF was observed. More precisely, we found an increase of 
WNT1, 7b and 10b, Fzd2 and 3, β-catenin, and Lef1 expression in IPF lungs and 
demonstrated a significant increase of WNT signaling in ATII cells derived from IPF patients. 
Immunohistochemical stainings revealed that β-catenin localization in ATII cells of IPF lungs 
is enhanced in the cytoplasm and nucleus, whereas it is more membranous in donor lungs, 
also indicating an activation of the signaling in IPF. 
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A.                                                             B.                  
       
 
Figure 6. Immunohistochemical stainings of β-catenin in ATII cells and fibroblasts in IPF lungs. 
(A) Cytoplasmatic and nuclear accumulation of β-catenin in ATII cells (arrow) 62. (B) Nuclear accumulation of 
β-catenin in fibroblasts in subepithelial fibroblast foci 61 
 
Furthermore, unbiased microarray screens have revealed an increased expression of WNT 
target genes, such as matrix metalloproteinase (Mmp) 7, or secreted frizzled-related protein 
(Sfrp) 2 in IPF 63,64. 
To reveal the functional significance of WNT/β-catenin signaling activation in IPF further 
investigation is required. Both, characterization of the stimuli that cause the β-catenin 
elevation and elucidation of the resulting mechanisms could provide new targets for inhibiting 
the progression of the disease. 
 
1.3.3 WT1-inducible signaling protein 1 in IPF 
WNT1-inducible signaling protein (WISP) 1 is encoded by the WNT target gene Wisp1 and 
was first discovered in a monkey epithelial cell line. It belongs to the CCN family of growth 
factors 65. This family consists of six regulatory, multimodular cysteine-rich proteins about 
30-40 kDa 66: cysteine-rich 61 (Cyr61/CCN1), connective tissue growth factor 
(CTGF/CCN2), nephroblastoma overexpressed (NOV/CCN3), WNT1-inducible signaling 
protein 1 (WISP1/CCN4), - 2 (WISP2/CCN5) and – 3 (WISP3/CCN6). 
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Figure 7. Scheme of CC family members and their functional domains 
67
. 
SP, Signal Peptide ; IGFBP, Insulin-like Growth Factor Binding Protein-like module ; VWC, Von Willebrand 
Factor-like module ; TSP1, Thrombospondin-like module ; CT, cysteine knot containing family of growth 
regulator-like module. HO : homology ; ID : identity 67. 
 
Their biological function comprises stimulation of mitosis, adhesion, apoptosis, ECM-
production, growth-arrest, and migration by transducing signals to target cells like fibroblasts, 
epithelial cells, endothelial cells, smooth muscle cells, and neuronal cells 66. Based on these 
functions, a role of CCN family members in developmental and pathologic processes is  
strongly suggested. However, acting mechanisms remain unclear. So far, an integrin-mediated 
signaling by binding and activating integrins at the cell surface is discussed at least for Cyr61 
and CTGF 68 that is followed by intracellular signal transduction. Wisp1 or Ccn4 was 
identified as a WNT/β-catenin downstream target gene that encodes a protein of 367 aa 69. Its 
messenger RNA (mRNA) was found to be upregulated in colon tumors 69. This observation 
accompanied by the ability of WISP1 to have antiapoptotic and proliferative effects on 
epithelial and mesenchymal cells, strongly indicate a role of WISP1 in tumorigenesis 70-74. For 
instance, it was already shown to be associated with epithelial cell hyperplasia in breast 
cancer cell lines 75 as well as its presence in lung cancer was described 76. In regard to lung, a 
novel role of WISP1 during IPF pathogenesis was recently revealed 77. In our laboratory 
increased secretion of WISP1 by alveolar epithelial cells type II (ATII) in IPF was observed 
by an unbiased approach. Furthermore our group found autocrine effects of WISP1 on the 
ATII cells, which exhibited hyperplasia and expression of profibrotic cytokines after WISP1 
treatment. In this context, also paracrine mechanisms of the ligand on fibroblasts seemed 
probable. 
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2. Hypothesis and aim of the study 
Idiopathic pulmonary fibrosis (IPF) is a devastating disease. It represents the most aggressive 
form of the idiopathic interstitial pneumonias (IIP). Unresponsive to any currently available 
therapy it exhibits the worst prognosis of the seven known IIPs 1,7-9.  
Despite of extensive research, many aspects of the pathomechanisms of IPF remain unclear. 
Currently, repetitive alveolar epithelial cell type II (ATII) injury and subsequent repair 
processes are considered as the initial trigger of the disease, which is followed by the 
activation of fibroblasts 4,7. Activated myofibroblasts form fibroblast foci, which represent 
hallmark lesions of IPF. They secrete abundant extracellular matrix (ECM), what finally leads 
to the fibrotic transformation of the lung 4,5,13,25-27. 
New mediators, which can influence the crosstalk between ATII cells and fibroblasts in this 
context and thereby trigger the progression of IPF were recently identified: WNT/β-catenin 
signaling has been demonstrated to be involved in the pathogenesis of IPF 61. In particular, it 
has been reported that WNT3a and WNT1-inducible signaling protein (WISP) 1 are secreted 
by ATII cells in IPF 62,77. It remains to be analyzed how the crosstalk between ATII cells and 
fibroblasts is affected by these proteins. 
 
 
Based on this rationale following was hypothesized for the present project: 
 
The proteins WT3a and WISP1, which are aberrantly secreted by ATII cells in IPF, 
act in a paracrine fashion on fibroblasts and thereby contribute to an impaired ATII cell 
– fibroblast crosstalk in the pathogenesis of IPF. 
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Figure 8. Hypothetical scheme to depict aberrant expression of WT3a and WISP1 by ATII cells, 
paracrine binding to lung fibroblasts and possible functional effects. 
 
To test this hypothesis following specific aims were formed: 
 
- Analysis of WNT/β-catenin pathway expression and activation in fibroblasts. 
- Analysis of the effects of WNT3a or WISP1 treatment on  
a) proliferation ([3H]-thymidine proliferation assay) 
b) collagen production (Sircol Collagen Assay) 
c) gene expression (qRT-PCR) 
 
 
 
 
 
 
 
 
 
WISP1
WT3a Paracrine binding on 
fibroblasts ???
Effects on proliferation, 
collagen depostiton, 
gene expression
???
Disorganised hyperplastic
alveolar epithelium
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3. Materials and Methods 
3.1 Materials 
3.1.1 Cells / Cell line 
NIH-3T3 fibroblasts (Swiss mouse embryo) German Collection of Microorganisms and Cell 
Cultures (DSMZ), Germany 
 
3.1.2 Machines / Software 
Fluorescence microscope; LEICA AS MDW  Leica, Germany 
Fusion A153601 Reader     Packard Bioscience, Germany 
GS-800TM Calibrated Densitometer   Bio-Rad, USA 
Nanodrop ND-100 spectrophotometer  Nanodrop Technologies, USA 
PCR-thermocycler      MJ Research, USA 
Quantity One software    Bio-Rad, USA 
7500 Fast Real-Time PCR System   Applied Biosystems, USA 
 
3.1.3 Reagents 
The following chemicals and reagents were purchased from the indicated companies. 
 
3.1.3.1 Chemicals and biochemicals 
Acetic acid      Roth, Germany 
Acetone      Merck, Germany 
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agarose      Promega, USA 
APS       Promega, Germany 
BSA        Sigma-Aldrich, Germany 
β-Mercaptoethanol     Sigma-Aldrich, Germany 
Bromphenol Blue     Sigma-Aldrich, Germany 
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CompleteTMProtease Inhibitor   Roche, Germany 
Dako Mounting medium    Dako, USA 
Dapi       Roche, Germany 
DNA Ladder 100bp     Promega, USA 
D-MEM      Gibco BRL, Germany 
EDTA       Promega, USA 
EGTA       Sigma-Aldrich, Germany 
Ethanol absolute     Riedel-de Haёn, Germany 
EtBr       Roth, Germany 
FCS        Gibco BRL, Germany 
Glycin       Roth, Germany 
Glycerol      Merck, Germany 
HCl       Sigma-Aldrich, Germany 
Igepal CA-630 (NP-40)    Sigma-Aldrich, Germany 
Methanol      Fluka, Germany 
NaCl       Merck, Germany 
Paraformaldehyde     Sigma-Aldrich, Germany 
PBS       PAA, Austria 
Quick Start™ Bradford Dye Reagent  Bio-Rad, USA 
Rotiszint Eco plus     Roth, Germany 
SDS       Promega, USA 
Sodium orthovanadate    Sigma-Aldrich, Germany 
TEMED      Bio-Rad, USA 
TRIS       Roth, Germany 
Trypsin/EDTA     Gibco BRL, Germany 
Tween-20      Sigma-Aldrich, Germany 
[3H]-thymidine     Amersham Biosciences, 
Piscataway, New Jersey 
 
3.1.3.2 Ligands, recombinant proteins 
WISP1/CCN4 (recombinant, human)  R&D Systems, USA 
WNT3a (recombinant, mouse)    R&D Systems, USA 
TGF-β1      R&D Systems, USA 
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3.1.3.3 qRT-PCR reagents 
dNTP-Mix      Promega, USA 
MgCl2, 50 mM     Invitrogen, Germany 
10x PCR buffer (without MgCl2)   Applied Biosystems, USA 
PCR Nucleotide Mix     Promega, USA 
Random Hexamers     Promega, USA 
RNase Inhibitor     Applied Biosystems, USA 
Reverse Transcriptase MuLV RT    Applied Biosystems, USA 
 
3.1.3.4 Antibodies 
primary antibody origin  dilution company, catalog number 
anti-αSMA  mouse  1:100  Sigma-Aldrich, Germany, A-2547  
anti-COLT1  rabbit  1:100  Chemicon, AB765P 
 
anti-Cyclin D1 rabbit  1:3000  Santa Cruz Bitotech, USA, sc-753 
anti-β-Catenin  rabbit  1:3000  Cell signalling, USA, 9562 
anti-Lamin a/c rabbit  1:3000  Santa Cruz Biotech, USA, sc-20681 
 
secondary antibody  origin  dilution company, catalog number 
Alexa 555 α rabbit IgG goat  1:1000  Invitrogen, Germany, A21429 
FITC α mouse IgG  goat  1:100  Dako, USA, F0479 
 
HRP α rabbit IgG  goat  1:3000  Pierce, USA, 31460 
 
3.1.3.5  Buffer 
for Protein extraction: Lysis-buffer: 
20 mM TRIS pH 7.5      
150 mM NaCl       
1 mM EDTA        
1 mM EGTA       
0.5 % NP-40 (= Igepal CA-630) 
CompleteTMProtease Inhibitor [40 µl/ml] 
Sodium orthovanadate Na3VO4    
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for DNA agarose  
gel electrophoresis:  1× TAE buffer: 
40 mM Tris-acetate, pH = 8.0 
1 mM EDTA, pH = 8.0      
 
for Western Blot analysis 10× SDS-loading buffer:  
625 mM Tris-HCl, pH = 6.8    
50 % (v/v) glycerol     
20 % (w/v) SDS     
9 % (v/v) β-mercaptoethanol     
0.3 % (w/v) bromophenol blue    
 
SDS-running buffer:   
25 mM Tris 
    50 mM glycine 
    0.1 % (w/v) SDS 
    
Transfer buffer: 
25 mM Tris 
192 mM glycine      
20 % (v/v) methanol 
 
1× PBST:      
1× PBS       
 0.1 % (v/v) Tween-20 
 
    1× TBST: 
    10 mM TRIS 7.5 pH 
    150 mM NaCl 
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Blocking solution:     
5 % (w/v) non-fat dry milk     
 1× PBST      
                or       
5 % (w/v) BSA 
1× TBST 
 
    Stripping buffer: 
    62.5 mM Tris-HCl, pH = 6.8 
    2 % (w/v) SDS 
    100 mM β-mercaptoethanol 
 
3.1.3.6 Gels 
Agarose gel:   1× TAE buffer 
0.2 % Agarose 
0.5 µg/µl EtBr 
 
Stacking gel:   5 % acrylamide: bisacrylamide  
125 mM Tris-HCl, pH = 6.8 
0.1 % (w/v) SDS 
0.1 % (w/v) APS 
0.1 % (v/v) TEMED 
 
Resolving gel:   10 % acrylamide: bisacrylamide  
375 mM Tris-HCl, pH = 8.8 
0.1 % (w/v) SDS 
0.1 % (w/v) APS 
0.1 % (v/v) TEMED 
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3.1.4 Kits 
       company, catalog number 
RNeasy Mini Kit     Qiagen, Germany, 74104 
RNase-free Dnase Set    Qiagen, Germany, 79254 
SircolTM, Soluble Collagen Assay   Biocolor, UK, S1000 
Platinum®SYBR®Green q PCR Super Mix-UDG Invitrogen, Germany 11733-04 
 
3.2 Methods 
3.2.1 Cell culture 
NIH-3T3 mousefibroblasts were cultured in DMEM, supplied with 10 % FCS and maintained 
in 250 ml culture flasks in an atmosphere of 95-100 % air humidity, 5 % CO2 at 37 °C. 
Passaging was carried out in an almost confluent stadium. After one washing step with 1× 
PBS, 3 ml of Trypsin/EDTA solution were added for 2 minutes (min) to catalyze their 
detachment from the underlay. This process was stopped by addition of 7 ml culture medium. 
Afterwards the 10 ml cell suspension either were distributed to new culture flasks in a dilution 
of 1:10 or seeded accordingly to protocols of upcoming experiments. For stimulation 
experiments, fibroblasts were kept in medium with reduced serum content of 0.5 % for at 
least 12 hours (h) to synchronize their metabolic activity before treatment. If not mentioned 
separately the final concentrations for WISP1 were 1 µg/ml and for WNT3a 100 ng/ml. 
 
3.2.2 [
3
H]-thymidine proliferation assay 
The proliferation assay is based on cleavage-dependent DNA incorporation of thymidine that 
is marked by the β-radiator 3H. The proliferation rate can be indirectly quantified by 
measuring the radioactive incorporated thymidine. 
Fibroblasts were seeded at a density of approximate 104/well on 48 well plates in 500  µl of 
culture medium. Adherent fibroblasts were synchronized in 0.5 % FCS medium and 
stimulated with WISP1 and WNT3a in 200 µl of 0.5 % and 5 % medium, respectively, for 
20 h. In the last 6 h of the stimulation, [3H]-thymidine [0.5 µCi/ml] was added to incorporate 
into the DNA of proliferating cells.   
Subsequently, fibroblasts were washed twice with PBS and lysed with 300 µl of sodium  
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hydroxide (NaOH) per well. 8 ml of Scintillation liquid were added to each sample. Then the 
measurement of residual radioactivity was performed with a β-scintillation counter, to asses 
occurrence of proliferation. 
 
3.2.3 Protein extraction and quantification 
Fibroblasts were plated on 10 cm diameter culture dishes or six well plates at a density of 
60 % or 90 %, respectively, and incubated until they were adherent. Synchronisation in 0.5 % 
FCS medium was followed by stimulation of the fibroblasts with WISP1, WNT3a or TGFβ-1. 
After the stimulation endpoints, proteins were lysed in lysis buffer (described in 3.1.3.5) and 
carefully harvested by scraping with a rubber policeman. The suspensions were transferred to 
Eppendorf tubes and incubated on ice for 30 min. During that time the tubes were vortexed 
each 10 min. After centrifugation at 13.000 rpm and +4 °C for 15 min, the supernatant 
containing the proteins was collected. 
The protein concentration in the cell extracts was determined colorimetrically using the 
Bradford Protein Assay. This method is used for measurement of the protein content in 
solutions. It is based on a change in the absorption spectrum of Coomassie Brilliant Blue G-
250 dye when the dye binds to cationic nonpolar and hydrophobic side chains of amino acids. 
After binding the reagent is stable in its deprotonated anionic sulfatic form. Accompanied by 
deprotonation it changes to a blue colour. The absorption maximum moves from 465 nm to 
595 nm. Accordingly, the absorption changes proportional to the amount of proteins in the 
sample. 
To perform the measurement, protein probes were diluted 1:10. Each sample was mixed with 
200 µl of the Bradford dye and transferred to a 96well plate. Different dilutions of bovine 
serum albumin (BSA) (0.05; 0.1; 0.2; 0.3; 0.4; 0.5; 0.6 µg/µl) were used as a protein standard 
to construct a protein standard curve.  
After 15 min incubation, the absorption was measured at a wavelength of 570 nm in a Fusion 
A153601 Reader. The corresponding protein concentrations were calculated by interpolation 
using the standard curve.  
 
3.2.4 SDS polyacrylamide gel electrophoresis 
In order to perform Western Blot analysis, protein extracts were separated by SDS 
polyacrylamide gel electrophoresis (SDS-Page). The dissociating agent SDS denatures the  
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proteins, binds to the polypeptides and provides a consistent negative charge to the 
polypeptides, so that they migrate to the positive electrode. The mobility of the proteins 
increases linear to the protein size. Smaller molecules migrate faster than larger ones and the 
proteins can be separated according to their molecular weight. For the separation two 
polyacrylamide gel layers were used: a resolving gel and a stacking gel, which were produced 
according to the recipe, described in 3.1.3.6. Ammonium persulfate (APS) and N,N,N,N,N`-
tetramethylenediamine (TEMED) were added at last to initiate the polymerisation of the gels. 
20 µg of each protein sample were mixed with 10× SDS-loading buffer and denaturated in a 
water bath at 100 °C for 5 min. After loading the proteins onto the gel, electrophoresis was 
performed in SDS-running buffer at 110 V. 
 
3.2.5 Immunoblotting 
After separation of the proteins by SDS-Page, immunoblotting (IB) was performed to 
visualize and detect specific proteins. The proteins were transferred to 0.25 µm pure 
nitrocellulose membrane in transfer buffer at 120 V for 1 h. Membranes were blocked in 
blocking solution at room temperature (RT) for 1 h. For blocking either PBST with 5 % milk 
or TBST with 5 % BSA were used, depending on manufacturers´ recommendations for the 
corresponding antibody. Afterwards the nitrocellulose membranes were incubated with the 
appropriate primary antibody, diluted in the blocking solution, at 4 °C overnight. 
Concentrations of the different antibodies are listed in 3.1.3.4. 
The incubation was followed by washing the membranes three times for 10 min with 1×TBST 
or 1×PBST, respectively, and then incubated with horse radish peroxidase labelled secondary 
anti-rabbit antibody for 1 h at RT. After washing, the protein detection was performed by 
chemiluminescence with the help of an enhanced chemiluminescence IB system and exposure 
to radiographic film. To be able to re-probe the membranes with another antibody, they were 
stripped with stripping buffer (described in 3.1.3.5) at 52 °C for 5 min, washed, blocked and 
subsequently treated with antibodies as described above. 
 
3.2.6. Densitometry 
To perform densitometric analysis, a GS-800TM Calibrated Densitometer and 1-D analysis 
software Quantity One were used. Protein expression was normalized to Lamin A/C levels, 
which served as a loading control. 
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3.2.7 Sircol Collagen Assay 
The Sircol Collagen Assay can be used for measuring collagen content of cells or tissues in 
vitro quantitatively by dye-binding. The dye contains Sirius Red Anions with acid sulphonic 
side chains that can bind to the basic amino acids of collagen, particularly to the helical [Gly-
x-y] n structure of all collagens. Specific binding to collagen is furthermore enforced by the 
parallel attachment of the long dye molecules to the likewise long and rigid triple helix 
structure of collagen II. 
According to the instructions, 50 µg of protein were taken from each sample and each mixed 
with 1 ml of the Sircol dye at room temperature for 30 min. Afterwards the samples were 
centrifuged for 10 min at 10 000 x g. The supernatant including unbound dye was aspirated 
carefully and 1 ml of Alkali solution was added to the pellet. Alkali solution contains 0.5 M 
NaOH and dissolves the dye from the dye-collagen-complex. Same procedure was performed 
with samples of acid soluble collagen type-1 [2.5; 5; 10; 20; 30; 40; 50 µg], which were used 
to construct a standard curve based on their absorption. Pellets were re-dissolved by vortexing 
and the samples as well as the collagen standards were transferred to a 96well plate in order to 
measure their absorption in a spectrophotometer at 540 nm. The calculation of the collagen 
content was performed via interpolation using the standard curve.  
 
3.2.8 RA isolation and measurement  
Isolation of total RNA from fibroblasts was performed according to the manufacturers’ 
instructions using the RNeasy Mini Kit. Furthermore, during the procedure a recommended 
DNase digestion was carried out with an RNase free DNase set to avoid any contamination 
with DNA. The concentration and quality of the obtained RNA was determined by measuring 
the optical density of the obtained solutions with a Nanodrop ND-100 spectrophotometer.  
The wave length for maximal absorption of nucleic acids is 260 nm. Absorption of single 
stranded (ss) RNA solution at this wave length is 1, when the concentration is 33 µg/ml. This 
is the so called Optical Density at 260 nm (OD260nm). 
Proteins, that often form a contamination source, have an absorption maximum of 280 nm. 
Hence, by calculating the quotient OD260nm/OD280nm the pureness of the nucleic acid could be 
assessed. The value should not be below 1.8 to exclude a contamination with proteins. The 
quotient of a pure RNA solution is 2.0. 
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3.2.9 cDA synthesis  
To be able to analyze the transcript (mRNA) level by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR), the RNA was transcribed into complementary cDNA. 
This process is catalyzed by reverse transcriptase (RT) an RNA-dependent DNA polymerase. 
The following protocol was used: 
500 ng RNA were used and if necessary put to a volume of 10 µl with RNase free water. 
The RNA samples were initially heated to 70 °C in a Thermo Cycler for 10 min. This 
denaturation step was followed by 5 min of cooling down and centrifugation. Then the 
Mastermix was added:  
 
Reagent       Volume Company 
10x PCR buffer (without MgCl2)   2 µl  Applied Biosystems, USA 
MgCl2 (25 mM)     4 µl  Invitrogen, Germany 
dNTPs       1 µl  Promega, USA 
Random Hexamers (50 µM)    1 µl  Promega, USA 
RNase Inhibitor (20 U/µl, 2000 U)   0.5 µl  Applied Biosystems, USA 
Reverse Transcriptase MuLV RT (50 U/µl, 5000 U) 1 µl  Applied Biosystems, USA 
ddH2O       0.5 µl 
∑ 10 µl + 10 µl RNA (500 ng) 
 
The Random Hexamers have a random base sequence and serve as primers that attach to 
ssRNA. The RT starts to put dNTPs in 5´-3´direction to the strand. The mixtures (20 µl) were 
transferred to the Thermo Cycler using the following protocol:  
1. Attachment of the Random Hexamers  20 °C for 10 min 
2. Reverse Transcription    43 °C for 75 min 
3. Inactivation of the Reverse Transcriptase  99 °C for 5 min 
4. Cooling      4 °C 
Obtained cDNA was storaged at -20 °C. 
 
3.2.10 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR)  
PCR is a method that allows the enzymatic amplification of any DNA/cDNA sequences in 
order to detect them. Each reaction cycle consists of three steps that run at different  
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temperatures: 1) denaturation of the DNA sample, 2) hybridisation of the primer 
oligonucleotides, and 3) elongation of the target sequence by a thermostabile DNA-dependent 
DNA polymerase. In 20-50 of such cycles the desired dsDNA product increases exponentially 
and can be detected. One entire PCR reaction can be distributed into four phases that refer to 
the manner of product increase: 
                                        
                                                   number of cycles 
 
Figure 9. Phases of a PCR reaction 
 
Semiquantitative PCR requires subsequent analysis of the PCR product, so called endpoint 
analysis. Mostly, the sequences are separated via gelelectrophoresis. During quantitative PCR, 
however, a simultaneously quantification of the initial amount of the amplificated sequence 
can be performed next to the amplification. Therefore, DNA-specific fluorescence signals are 
used. Those conduct proportional to the product accumulation and are measured during the 
reaction and the end of each cycle respectively. Hence, all data are obtained in „real-time“. 
Additional working steps are not necessary, which decreases the risk of contamination 
considerably.  
 
3.2.10.1 Measurement of fluorescence with SYBR Green I 
One possibility of online-detection is the fluorescence measurement with SYBR Green I, an 
asymmetric cyanine dye that binds sequence independently to the minor grooves of double 
stranded (ds) DNA. The emission of fluorescent light of the bound dye increases 1000-fold 
compared to the free dye. Thus, product (dsDNA) accumulation can be detected by signal 
increase. This occurs firstly in the hybridisation (annealing) phase, when the primer binds to 
the ssDNA and steadily increases until the end of the elongation phase. Measurement is  
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performed at the end of the elongation phase of each cycle because then the amount of 
dsDNA and therefore also the fluorescence intensity reach their maxima. The occurrence of 
non-specific products like primerdimers alters the amplification efficiency and thereby causes 
a systematic quantification error that has to be avoided by optimising the quantitative 
analysis. In sequence-specific detection methods these non-specific products also occur but 
are not detected. Thus, with SYBR Green I a further characterization of the used primerset is 
allowed which the sequence-specific detection is lacking 78.  
 
3.2.10.2 Primerdesign and efficiency test 
Primer sequences were taken from gene bank of the NCBI. The design of the definite primers 
was carried out with the program primer express 3.0, considering the following criteria as 
accurately as possible: 
- length about 20 – 30 nucleotides to ensure a relatively high annealing temperature. 
- almost same frequency of each of the four bases. 
- not suitable are regions with particular sequence parts (oligopurine, oligopyrimidin) 
and regions with pronounced secondary structure. 
- avoiding of homo and heterodimeric complementarity at the 3` end that could increase 
the development of primer dimers. 
- optimal annealing temperature: > 45 °C. 
- to minimize unspecific binding primers should have strong binding 5` and less strong 
binding 3` ends. 
- melting temperature should be the same for both primers of a pair (forward and 
reverse). 
- Estimation of melting temperature, if number of nucleotides is ≥ 20: Tm = [(Number of 
A + T) × 2 °C + (Number of G + C) × 4 °C]. 
For each primer pair the amplification efficiency was determined by serial dilution 
experiments with at least two dilution steps to cover a high dynamic range. The amplification 
efficiency should have a value between 1.8 and 2.0. 
The primers listed in Table 3 (6.1) were used at a final concentration of 200 nM. 
Porphobilinogen deaminase (Pbgd), an ubiquitously and constitutively expressed gene in 
mice cells that is free of pseudogenes, was used as a reference gene in all qRT-PCR reactions. 
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3.2.10.3 Melting curve analysis 
SYBR Green I binds to any dsDNA. A melting curve analysis allows the identification of the 
PCR product because of temperature-dependent signal decrease as a consequence of the 
melting of the product. By definition, the melting temperature (Tm) describes the temperature 
at which half of the DNA is present as a denaturated single strand. Tm is characterized by 
length and GC content of the dsDNA. 
After the 45 PCR cycles, the samples are heated slowly to 90 °C, the products denature at 
different timepoints and different temperatures, respectively. Melting is accompanied by 
release of SYBR Green I and thus a rapid decrease of fluorescence. The timepoint of 
fluorescence decline allows concluding the Tm. Unspecific products, such as primerdimers, 
are shorter (40 - 45 basepares (bp)) compared to the amplicon (100 - 200 bp). Thus, they have 
a lower melting temperature. 
In the negative derivative of the melting curve each peak value represents a Tm. As the Tm 
deviate between specific and non-specific product, the melting curve allows to confirm the 
amplification of the correct target. Furthermore the area under the curve (AUC) of the 
maxima is proportional to the product amount 78.  
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Melting curves 
Melting curves of two primersets with different Tm. Detected primerdimers are marked with an arrow. 
 
3.2.10.4 Quantification and analysis of data 
To analyze the data, the fluorescence signal is plotted against the number of cycles 
(amplification plot). The baseline of this graph is determined by the initial phase that 
corresponds to the cycles in which the fluorescence has not yet started to increase 
considerably. 
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The crucial point for quantification is the exponential phase of product accumulation. In this 
phase, the so-called “threshold” regarding the fluorescence signal has to be assessed. For one 
gene this value should not change between different samples and runs. The cycle number 
when the signal reaches this threshold is called Ct (threshold cycle) or crossing point. It 
depends linear on the logarithm of the initial product concentration and therefore allows its 
determination. To obtain a relative quantification of the mRNA level of the wanted gene, their 
Ct values were analyzed as the difference to the reference gene Pbgd: ∆Ct = Ct reference 
gene – Ct gene x. Aim of this work was to judge the effects of stimulation on gene expression. 
Therefore, the relative mRNA level changes of the stimulated samples compared to the 
unstimulated controls were determined and expressed as ∆∆Ct. ∆∆Ct = ∆Ct stimulated – ∆Ct 
control. The ∆∆Ct corresponds to the binary logarithm of the fold change. 
 
3.2.11 DA agarose gelelectrophoresis 
Agarose gel electrophoresis is a method to separate and visualize DNA fragments according 
to their size. Negatively charged nucleic acids are moved through the electric field in the gel. 
The shorter a molecule is, the faster it moves through the gel, what means, that after a certain 
time period short molecules have covered a longer distance than longer ones. For the 2 % gel, 
agarose was mixed with 1× TAE buffer. It was additionally supplied with 0.5 µg/µl ethidium 
bromide (EtBr) to make the fragments visible. EtBr is a dye that intercalates with DNA and 
fluoresces under ultraviolet light. Before loading onto the gel covered by 1× TAE buffer, the 
undiluted and 1:10 diluted DNA samples were mixed with 6× DNA loading buffer. Same was 
performed with the empty control sample. Then electrophoresis was run at 100 V/cm. 
 
3.2.12 Immunofluorescence 
Immunofluorescence enables the detection of antigen structures in cells with the help of 
antibodies. Here, immunofluorescence labeling with fluorochroms was used in order to 
visualize and localize selectively macromolecules inside the cell. Cells are incubated with a 
first antibody against the antigen to be analyzed. Next step is the binding of a specific 
fluorchromalized secondary antibody against the first one. Then the localizations of binding 
can be observed with a fluorescence microscope. The experiment was performed as 
following: 15000 fibroblasts per well were plated on special chamber slides. After attachment, 
synchronisation and stimulation (see above) cells were fixed with acetone/methanol (1:1). To  
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avoid unspecific binding a blocking step was performed with PBS enriched with 10 % (m/vol) 
BSA for at least 1 h followed by incubation with the first antibody in accordant dilutions. For 
secondary binding antibodies were also used in the appropriate dilutions, conjugated with 
either fluorescein-5-isothiocyanate (FITC) or AlexaFluor. Nuclei were visualized by labeling 
with 4´.6-diamidino-2-phenylindole (DAPI). After incubation, the fibroblasts were fixed with 
4 % paraformaldehyde and the slides were covered with DAKO. The fibroblasts were viewed 
with an immunofluorescence microscope and pictures were taken with a Leica Q Win 
program. 
 
3.2.13 Statistical analysis  
Proliferation assay data were analyzed using the Wilcoxon Rank sum test and the Signed 
Rank test. All ∆∆Ct values obtained from qRT-PCR and densitometry results from Western 
Blots were analyzed using the two-tailed, one-sample t-test. All p values obtained from 
multiple tests were adjusted using the procedure from Benjamini & Hochberg 79. Results were 
considered statistically significant when p < 0.05 (* p < 0.05). 
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4. Results 
4.1 Analysis of occurrence of WT/β-catenin signaling in 
fibroblasts 
4.1.1 Phenotype of IH-3T3 fibroblasts 
As a fibroblast cell line NIH-3T3 cells are supposed to produce and secrete collagen. To 
determine the expression of type I collagen, indirect immunofluorescence was performed with 
rabbit anti-collagen type 1 antibody (anti-COLT1). In the cytoplasm of almost all fibroblasts 
collagen expression was observed (Figure 11.A.). Extracellular staining indicated secretion of 
collagen and thus pointed to its role as extracellular matrix (ECM) component (Figure 11.A. 
arrows). Alpha smooth muscle actin (αSMA) is known as a (myo-) fibroblast activation 
marker. In order to ensure that no autoactivation of the cells takes place during culture, 
expression of this marker was checked with mouse anti-αSMA antibody. Only few cells 
exhibited SMA expression (Figure 11.B).  
A.  
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
Figure 11. Localization and presence of COLT1 and αSMA in the fibroblast cell line IH-3T3 
(A) Immunofluorescent detection of COLT1 expression with secondary Alexa 555-labelled antibody (red) 
(original magnification from left to right: 10×, 20× and 40×). Extracellular staining is marked with arrows. (B) 
Immunofluorescent detection of αSMA with secondary FITC-labelled antibody (green) (original magnification 
from left to right: 10×, 20× and 40×). Cell nuclei were visualized by DAPI staining (blue). All pictures are 
representative for at least three independent experiments. 
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4.1.2 Expression analysis of WT pathway components in fibroblasts 
To investigate, whether WNT signaling can take place in fibroblasts, the expression of WNT 
pathway components was analyzed. Therefore, the expression of WNT ligands, receptors, 
coreceptors and intracellular components of the signaling cascade was determined by qRT-
PCR. Investigated WNT encoding genes were Wnt1, Wnt3a, Wnt8b, Wnt10a, Wnt10b and 
Wnt11. On the receptor level primers for Frizzleds (Fzds) 1-8 and the coreceptors lipoprotein 
receptor-related protein (Lrp) 5 and 6 were analyzed. Additionally, mRNA levels of the 
intracellular pathway components β-catenin (β-cat) and glycogen synthase kinase (Gsk) 3β, T-
cell-specific transcription factor (Tcf) 1, 3 and 4 and lymphoid enhancer-binding factor (Lef) 
were assessed (compare dissociation curves in 6.2). 
Primer efficiency was determined as indicated in 3.2.10.2. PCR products were visualized by 
DNA agarose electrophoresis. While the quantification during the PCR run was performed 
simultaneously to the amplification cycles, the gel electrophoresis formed an endpoint 
analysis after all 45 cycles. Thus, even for molecules, that are not used for quantification (“not 
expressed”), product length, as well as melting temperature can be analyzed (compare 6.2, 
Figure 20). Specific PCR products are shown in Figure 12.A. 
To further quantify the gene expression, relative mRNA levels were determined. In Figure 
12.B. they are presented as ∆Ct. All WNT ligands were low expressed compared to the 
reference gene Pbgd. Wnt3a and Wnt11 were not expressed (n.e.) at all (Figure 12.B first 
diagram). On the receptor level, mRNA of all analyzed Fzds was present, except of Fzd6 and 
8. The ∆CT values of Fzd2 and 7 revealed high expression of these receptors. Same pattern 
occurred for the coreceptor Lrp6 (Figure 12.B second diagram). β-cat and Gsk3β, key 
molecules of canonical WNT signaling were highly expressed. Also the presence of 
transcription factors Tcf3 and Tcf4 was observed, whereas Tcf1 and Lef1 revealed no or low 
expression (Figure 12.B third diagram).  
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Figure 12. mRA expression of WT pathway components in lung fibroblasts 
(A) Agarose gel electrophoresis of PCR products. Gels are representative for three independent experiments.  
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B.         
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. mRA expression of WT pathway components in lung fibroblasts 
(B)  Relative mRNA level of relevant molecules were determined via qRT PCR. Pbgd was used as a reference 
gene. For each pair of primers the ∆Ct value is shown. Expression pattern of WNT ligands, WNT receptors and 
coreceptors and intracellular components of the pathway. 
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4.1.3 Induction of WT/β-catenin signaling in fibroblasts by stimulation 
with WT3a 
In order to check if WNT/β-catenin signaling can be operable in fibroblasts, protein 
expression of β-catenin (β-CAT) and CyclinD1 (CYCD1), a known target molecule of 
canonical signaling, was examined via Western blot analysis after stimulation with WNT3a. 
The blots revealed increased levels of total β-catenin after stimulation for 3, 6, and 12 h 
(Figure 13.A). These results were confirmed by densitometric analysis. Statistically 
significant was the upregulation after 6 h (Figure 13.B). CYCD1 protein expression was 
enhanced as early as 6 h after WNT3a treatment (Figure 13.A).  
To further corroborate the activation of the canonical WNT signaling pathway, mRNA level 
of the known target genes WNT inducible signaling protein (Wisp) 1 and CycD1 were 
quantified by qRT-PCR. The results of qRT-PCR are presented as mean of ∆∆Ct ± s.e.m. In 
accordance to the increasing protein level, the mRNA expression of CycD1 was increased 
significantly 6 h after treatment (6 h: 2.75 ± 0.67, 12 h: 1.71 ± 0.69). (Figure 13.C). Increased 
expression of Wisp1 was observed after 12 h (6 h: 1.57 ± 0.94, 12 h: 1.03 ± 0.26) (Figure 
13.C). 
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B.  
 
 
 
 
 
 
 
 
 
 
 
C.  
 
 
 
 
 
 
 
 
 
Figure 13. WT responsiveness of  fibroblasts. 
(A) β-Catenin and CYCD1 protein expression levels of control and WNT3a [100 ng/ml]-treated fibroblasts for 3, 
6 and 12 h assessed by IB. Lamin a/c served as a protein loading control. Blots are representative for three 
independent experiments. (B) The results obtained by IB were densitometrically analyzed (n=3, * p< 0.05), 
statistical analysis included two-tailed t-test. (C) Fibroblasts were stimulated with WNT3a (100 ng/ml; 6 or 12 h, 
as indicated mRNA level of WNT target genes CycD1 and Wisp1 were determined via qRT-PCR. Pbgd was 
used as a reference gene. Results are presented as mean of ∆∆Ct ± s.e.m. (n=3, *p< 0.05). 
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4.2 Functional analysis of paracrine effects of WT3a on 
fibroblasts 
4.2.1 Effects of WT3a on lung fibroblast proliferation 
The WNT/β-catenin signaling pathway was found to be activated in lung fibroblasts after 
stimulation with WNT3a (comp. 4.1.3). In order to investigate its functional relevance, 
potential effects of WNT3a on cell proliferation were analyzed. Cell proliferation was 
quantified using the 3[H]-thymidine proliferation assay. First, fibroblast proliferation due to 
varying serum conditions was determined. As expected, proliferation of the fibroblasts 
elevated with increased fetal calf serum (FCS) content (Figure 14.A). Interestingly, fibroblasts 
stimulated with WNT3a for 20 h in the presence of different concentrations of FCS (0.5 % or 
5 % FCS, respectively) did not reveal any significant changes in the proliferation compared 
with the unstimulated control (108 % ± 13 % and 96 % ± 13 %, respectively ) (Figure 15.B 
and C). 
 
A. 
 
 
 
 
 
 
 
B.         C.  
 
 
 
 
 
 
 
Figure 14. Proliferation of lung fibroblasts after stimulation with WT3a 
Proliferation of fibroblasts was assessed with 3[H]-thymidine proliferation assay. (A) Absolute proliferation 
[cpm] in different serum conditions. (B) Relative proliferation in medium with 0.5 % FCS after 20 h stimulation 
with 100 ng/ml WNT3a. Cells from unstimulated medium of the same condition were used as control. (n=3) (C) 
Relative proliferation in medium with 5 % FCS after 20 h stimulation with 100 ng/ml WNT3a. (n=3) 
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4.2.2 Effects of WT3a on collagen deposition of lung fibroblasts 
Enhanced extracellular matrix (ECM) deposition and collagen production of activated 
myofibroblasts is one of the key events in IPF pathogenesis. To examine a potential role of 
WNT/β-catenin signaling on this profibrotic processes, the collagen content was determined 
by immunofluorescence and quantified by Sircol Collagen Assay. For indirect 
immunofluorescence fibroblasts were stimulated with WNT3a in D-MEM, supplied with 
0.5 % or 10 % FCS, respectively. Collagen type I was assessed using a rabbit anti-COLT1 
antibody. In both serum conditions, specific collagen expression was observed in the 
cytoplasm of stimulated and unstimulated fibroblasts (Figure 15.A and B). Cells incubated in 
0.5 % FCS generally showed slighter staining (Figure 15.A), whereas 10 % FCS led to a 
stronger collagen staining in the cytoplasm as well as extracellular, indicating production and 
secretion of collagen type I by fibroblasts in response to WNT3a (Figure 15. B arrow). 
To further quantify the amount of collagen production, the total collagen content was 
determined using the Sircol Assay. Fibroblasts treated with TGF-β1, which is a well known 
mediator of increased collagen production in fibroblasts 80, were used as a positive control. 
The whole experiment was performed with fibroblasts in a subconfluent growth stadium 
(60 %) as well as in almost confluency (90 %). After stimulation with WNT3a at 
subconfluency, fibroblasts exhibited significant elevation of collagen contenbout 3 ± 0.4 fold 
change, while TGF-β1 stimulated fibroblasts exhibited a 2.5 ± 0.2 fold change (Figure 15.C). 
Under confluent conditions fibroblasts exhibited a lower increase of collagen content (1.4 ± 
0.1 fold for TGF-β1 and 1.6 ± 0.09 fold for WNT3a) (Figure 15.D). 
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Figure 15. Localization and content of collagen in fibroblasts after stimulation with WT3a 
(A) + (B) Cell nuclei were visualized by DAPI staining (blue). Immunofluorescent detection of COLT1 
expression with secondary Alexa 555-labelled antibody (red) (original magnification upper row: 20×, lower row: 
40×).  (A) COLT1 staining after stimulation with WNT3a in medium with 0.5 % FCS. (B) COLT1 staining after 
stimulation with WNT3a in medium with 10 % FCS. All pictures are representative for three independent 
experiments. Extracellular staining is marked with arrows. 
 
 
control WT3a
20x
40x
control WT3a
20x
40x
4. Results 40 
 
C.           D.      
         .  
 
 
 
 
 
 
 
 
Figure 15. Localization and content of collagen in fibroblasts after stimulation with WT3a 
 (C) + (D) Collagen content of fibroblasts after stimulation with 100 ng/ml of WNT3a was determined with 
Sircol Assay and is shown relative to the unstimulated control. TGF-β1 stimulated cells were used as a positive 
control. (n=3, *p< 0.05) (C) Changes in collagen content of fibroblasts that were stimulated in a subconfluent 
stadium. (D) Changes in collagen content of fibroblasts that were stimulated in almost confluent stadium.  
 
4.2.3 Effects of WT3a on gene expression of ECM molecules and (myo-) 
fibroblast markers  
Enhanced collagen production of fibroblasts after WNT3a stimulation had suggested 
profibrotic effects of WNT/β-catenin signaling on fibroblasts. To further confirm these effects 
and reveal other potential pathomechanisms, the mRNA level of different profibrotic marker 
genes were analyzed using qRT-PCR after WNT3a treatment for 6 and 12 h. Interestingly, the 
expression of type I collagen alpha 1 (Col1a1) and type I collagen alpha 2 (Col1a2) was not 
significantly altered after stimulation (mean of ∆∆CT ± s.e.m.: Col1a1 6 h: -0.28 ± 0.11, 12 h: 
-0.76 ± 0.32, Figure 16.A). In addition, the expression of the glycoprotein fibronectin1 (Fn1), 
an ECM component that plays a role in stabilizing the attachment of the ECM, was not 
significantly affected by WNT3a treatment (6 h: 0.76 ± 0.71, 12 h: -0.82 ±-0.14). 
In contrast, a significant increase of the (myo-) fibroblast activation marker alpha smooth 
muscle actin (αSma) was observed after 6 h stimulation (6 h: 0.9 ± 0.17, 12 h: 0.64 ± 0.3). 
Additional fibroblast markers, such as the fibroblast specific protein 1 (Fsp1), also known as 
S100a4, and Vimentin were not differently expressed (6 h: 1.09 ± 0.83, 12 h: -0.33 ± 0.65 and 
6 h: -0.32 ± 0.34, 12 h: 0.04 ± 0.37 respectively, Figure 16.B). 
The cytokine transforming growth factor (TGF) -β is already known to play a role in IPF 
pathogenesis. It can act in a profibrotic way by driving EMT, fibroblast activation, and 
induction of ECM production 26. 
 
 
0
1
2
3
4
control WT3a TGF-〒1
re
la
ti
v
e 
co
ll
a
g
en
 c
o
n
te
n
t
**
0
1
2
3
4
control WT3a TGF-〒1
*
*
re
la
ti
v
e 
co
ll
a
g
en
 c
o
n
te
n
t
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To analyze a possible crosstalk between WNT and TGF-β signaling the effects of WNT 
treatment on the expression of Tgfβ-1 were checked additionally. Neither after 6 nor after 12 h 
significant changes were observed (6 h: 0.22 ± 0.82, 12 h: 0.25 ± 0.12, Figure 16.C). 
Furthermore, the expression of arginase (Arg) 1 and 2 was examined, as arginase mediates 
collagen deposition in lung fibrosis 81. Therefore a responsibility for the collagen increase on 
protein level after WNT3a treatment can be suggested. Both enzymes were not affected 
significantly after stimulation (6 h: -1.53 ± 0.91, 12 h: -0.83 ± 0.67 and 6 h: 0.12 ± 0.89, 12 h: 
-0.96 ± 0.96 respectively, Figure 16.C).  
Taken together, these results revealed that WNT can contribute to fibroblast activation and is 
a potent inducer of collagen in fibroblasts, however our analysis thus far suggests that WNT 
signaling does not interfere directly with the transcriptional regulation of collagens. 
 
 
A.  
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Figure 16. mRA level of ECM molecules and (myo-) fibroblast markers after stimulation with WT3a 
Fibroblasts were stimulated with WNT3a (100 ng/ml; 6 or 12 h, as indicated), and the mRNA levels of different 
ECM components or (myo-) fibroblast activation markers were analyzed by qRT-PCR (n=4). Results are 
presented as mean of ∆∆CT ± s.e.m., * p < 0.05. 
(A) ∆∆CT of ECM components. (B) ∆∆CT of (myo-) fibroblast markers. (C) ∆∆CT of possible crosstalk 
partners. 
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4.3 Functional Analysis of effects of WISP1 on fibroblasts 
The WNT1-inducible signaling protein (WISP) 1 is encoded by a target gene of WNT/β-
catenin signaling. In our laboratory high secretion of WISP1 by distorted ATII cells of IPF 
lungs has already been observed. To analyze, if WISP is a mediator for the reported WNT 
effects, the effects of WISP1 treatment on fibroblast proliferation, collagen content and 
marker gene expression were investigated, similar to the approaches described above. 
4.3.1 Effects of WISP1 on fibroblast proliferation 
Cell proliferation was assessed using the 3[H]-thymidine proliferation assay. Fibroblasts 
stimulated with WISP1 in medium either supplied with 0.5 % or 5 % FCS for 20 h did not 
reveal significant changes in the proliferation compared to the respective control (89 % ± 8 % 
and 105 % ± 9 %, respectively). (Figure 17.A and B). 
 
 
A.         B.   
 
 
 
 
 
 
 
 
Figure 17. Proliferation of lung fibroblasts after stimulation with WISP1 
Proliferation of fibroblasts was assessed with 3[H]-thymidine proliferation assay. (n=3) (A) Relative proliferation 
in medium with 0.5 % FCS after 20 h stimulation with 1 µg/ml WISP1. (B) Relative proliferation in medium 
with 5 % FCS after 20 h stimulation with 1 µg/ml WISP1. 
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4.3.2 Effects of WISP1 on collagen deposition of fibroblasts 
To analyze WISP1 effect on matrix deposition during IPF, collagen deposition of fibroblasts 
was assessed after stimulation with WISP1. Immunofluorescence and Sircol Collagen Assay 
were performed to determine and quantify collagen content in the fibroblasts, respectively. 
For indirect immunofluorescence fibroblasts were stimulated with WISP1 in D-MEM, 
supplied with 0.5 % or 10 % FCS, respectively. Collagen type I was assessed using a rabbit 
anti-COLT1 antibody. In both serum conditions, specific collagen expression was observed in 
the cytoplasm of the fibroblasts, similar to the localization patterns in 4.2.2. Stimulated cells 
exhibited specific collagen staining in the cytoplasm (Figure 18.A+B). The staining after 
incubation in 0.5 % FCS–medium was slighter than in 10 %. But in both serum conditions, 
control and WISP1 stimulated cells exhibited distinct cytoplasmic and extracellular (arrow) 
collagen staining pattern (Figure 18.A+B). 
To determine collagen quantity in the fibroblasts after WISP1 treatment, Sircol Collagen 
Assay was performed. The collagen content was determined 20 h after stimulation with 
WISP1. Fibroblasts stimulated with TGF-β1 were used as a positive control. The whole 
experiment was performed with fibroblasts in a subconfluent growth stadium (60 %) and in 
almost confluency (90 %). After stimulation with WISP1 at subconfluency, fibroblasts 
exhibited significant elevation of collagen content about 2.4 ± 0.1 fold change (Figure 18.C). 
Under confluent conditions, fibroblasts revealed significant increases of collagen content of 
1.5 ± 0.2 fold change after stimulation with WISP1 (Figure 18.D). 
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Figure 18. Localization and content of collagen in lung fibroblasts after stimulation with WISP1 
(A) + (B) Cell nuclei were visualized by DAPI staining (blue). Immunofluorescent detection of COLT1 
expression with secondary Alexa 555-labelled antibody (red) (original magnification upper row: 20×, lower row: 
40×). (A) COLT1 staining after stimulation with WISP1 in medium with 0.5 % FCS. (B) COLT1 staining after 
stimulation with WISP1 in medium with 10 % FCS. All pictures are representative of three independent 
experiments. Extracellular staining is marked with arrows. 
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C.              D.  
 
 
 
 
 
 
 
 
Figure 18. Localization and content of collagen in lung fibroblasts after stimulation with WISP1 
 (C) + (D) Collagen content of fibroblasts after stimulation with 1 µg/ml of WISP1 was determined with Sircol 
Assay and is shown relative to the unstimulated control. TGF-β1 stimulated cells were used as a positive control. 
(n=3, *p< 0.05) (C) Changes in collagen content of fibroblasts that were stimulated in a subconfluent stadium. 
(D) Changes in collagen content of fibroblasts that were stimulated in almost confluent stadium. 
 
4.3.3 Effects of WISP1 on gene expression of ECM molecules and (myo-) 
fibroblast markers  
Enhanced collagen content in fibroblasts after stimulation with WISP1 as well as its upstream 
molecule WNT3a had indicated profibrotic effects of the pathway on fibroblasts. To 
investigate if WISP1 acts as a mediator leading to fibroblast activation and collagen transcript 
expression, different genes were analyzed using qRT-PCR after WISP1 treatment for 6 and 
12 h, as described above after WNT3a stimulation. The results of qRT-PCR are presented as 
mean of ∆∆Ct ± s.e.m. Following factors belonging to the ECM were determined: Col1α1, 
Col1α2, collagen 4 (Col4), collagen 7 (Col7) and Fn1. Col1a1 and Col1a2 were regulated by 
WISP1 (Figure 19.A). After 12 h significant increase of the expression of both could be 
observed: ∆∆Ct ± s.e.m. of 2.5 ± 0.52 for Col1a1 and 3.02 ± 0.82 for Col1a2. Interestingly, 
Col4 expression was enhanced after 6 h (6 h: 1.76 ± 0.6), but significantly downregulated 
after 12 h (12 h; -1.61 ± 0.78). Col7 was generally low expressed in the fibroblasts (∆CT not 
shown) and not altered significantly (6 h: 0.18 ± 0.42, 12 h: -0.93 ± 0.51). Fn1 expression 
exhibited a significant increase after 6 h of stimulation, whereas after 12 h no changes were 
observed (6 h: 1.02 ± 0.29, 12 h: -0.05 ± 0.3, Figure 19.A). Next, a possible influence of 
WISP1 on fibroblast activation was checked by examining the expression levels of typical 
(myo-) fibroblast activation markers. The expression of αSma was increased significantly  
after 6 h stimulation (6 h: 0.62 ± 0.09, 12 h: 0.15 ± 0.22). Fsp1 expression was enhanced at  
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both timepoints (6 h: 0.46 ± 0.18, 12 h: 0.67 ± 0.23). The mRNA level of Vim were not 
changed (6 h: -0.36 ± 0.31, 12 h: -0.07 ± 0.35, Figure 19.B).  
Next to the crucial role of the TGF-β system in IPF 26, a role of Plasminogen activator 
inhibitor (PAI) -1 was already reported 82. To reveal possible crosstalks to these signaling 
pathways, expression of Pai1 and Tgf-β1 in fibroblasts was analyzed after stimulation with 
WISP1. Pai1 was upregulated after 12 h (6 h: -0.91 ± 0.09, 12 h: 0.96 ± 0.47), whereas TGF-
β1 was not altered on mRNA level after WISP1 treatment (6 h: 0.04 ± 0.22, 12 h: -0.08 ± 
0.09, Figure 19.C). 
In summary, our results revealed that WISP1 can induce collagen expression in fibroblasts on 
transcriptional and protein level. Furthermore, it led to an increased expression of ECM 
components and (myo-) fibroblast activation markers. 
 
 A.  
 
 
 
 
 
 
 
 
B.            C.  
 
 
 
 
 
 
 
 
Figure 1. mRA level of ECM molecules and fibroblast markers after stimulation with WISP1 
Fibroblasts were stimulated with WISP1 (1 µg/ml; 6 or 12 h, as indicated), and the mRNA levels of different 
ECM components or (myo-) fibroblast activation markers were analyzed by qRT-PCR (n=4). Results are 
presented as mean of ∆∆CT ± s.e.m., * p < 0.05.  
(A) ∆∆CT of ECM components. (B) ∆∆CT of (myo-) fibroblast markers. (C) ∆∆CT of possible crosstalk 
partners. 
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5. Discussion 
5.1. Fibroblasts in IPF pathogenesis 
Idiopathic pulmonary fibrosis (IPF) represents the most common and most severe form of the 
idiopathic interstitial pneumonias (IIP). In spite of extensive research on the field, the 
pathomechanisms are still not understood. Refractory to medicamentous therapy the disease 
rapidly leads to the death of the patient because of respiratory failure. 
The initiation of the disease currently is ascribed to alveolar epithelial cell injury and 
subsequent inadequate repairmechanisms 2,7,18. 
In the present study fibroblasts as key effector cells in the pathogenesis of IPF were in the 
focus of our research. Being activated to myofibroblasts and forming fibroblast foci that are 
responsible for an extensive collagen-rich extracellular matrix accumulation in the 
interstitium of the lung, fibroblasts are considered as triggers for the progression of the 
disease 26,27. However, the origin of these fibroblasts remains unclear. As one possible origin 
for the fibroblasts, bone marrow-derived fibrocytes are discussed 83. Circulating to the lung 
during fibrosis, they could serve as precursors for the interstitial fibroblasts 84-86. A second 
theory claims epithelial-to-mesenchymal transition (EMT) being the source of the fibroblasts. 
It includes a phenotypic switch of epithelial to fibroblast-like cells, subsequently to changes in 
gene and protein expression of ATII cells 87-89.  
Thirdly, a possible role of local growth factors and cytokines triggering the activation and 
differentiation of the fibroblasts is well accepted 8,28,90. Source of profibrotic molecules are 
probably hyperplastic ATII cells that are known to express growth factors like transforming 
growth factor-β1 (TGF-β1), platelet derived growth factor (PDGF), and the cytokine tumor 
necrosis factor-α (TNF-α) 7,12. TGF-β1 as one example has profibrotic effects in human lung 
fibroblasts, inducing an altered secretion of collagens and total ECM and thereby influencing 
the pathogenesis of IPF 26,80.  
The present report was focused on the third theory by analysing possible trigger molecules 
that could have paracrine effects on lung fibroblasts and thereby contribute to the 
development of the fibroblast phenotype that is found in IPF. 
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5.2. WT/β-catenin signaling in lung fibroblasts 
In regard to the pathophysiological mechanisms of IPF progression, the WNT/β-catenin 
system is of particular interest. On the one hand, a role of WNT/β-catenin signaling in 
different diseases is well established. On the other hand, presence of WNT in the respiratory 
system can be stated. It is functionally involved in lung development as well as in lung 
cancer 31,35,50,51,91. Increased WNT/β-catenin signaling in IPF was reported by Chilosi et al. 
(2003) 61 and recently by our group 62,77. 
WNT/β-catenin signaling is neither limited to a special tissue nor to a cell type. Actually, the 
functional response differs cell type specific 35. Therefore in every tissue and organ it is 
important to examine different cell types and their affection by WNT signaling separately. 
This project focused on lung fibroblasts and their relation to WNT/β-catenin signaling in IPF. 
Several reports deal with WNT/β-catenin signaling in fibroblasts. Recently, WNT 
responsiveness and induction of already known and also new target genes in human 
fibroblasts were described 92. In their publication about aberrant WNT/β-catenin pathway 
activation in IPF, Chilosi and colleagues (2003) reported nuclear β-catenin accumulation in 
fibroblasts based on immunohistochemical observations 61. Thus, the conclusion stands to 
reason that lung fibroblasts constitute WNT target cells in association with IPF. This was 
recently emphasized by our report about functional WNT signaling in IPF that examines cell-
specific expression patterns of WNT ligands and pathway components 62. Although receptors 
and intracellular signal transducers of the WNT/β-catenin pathway mainly localize in the 
bronchial and alveolar epithelium, primary human fibroblasts also exhibited presence of these 
pathway components. These observations underline the suggestion that paracrine extracellular 
WNT binding can activate the downstream signaling pathway inside the cell. 
Additionally to the expression and localization analysis, an increased phosphorylation of 
WNT signal transducing molecules in IPF was observed 62, which is the most sensitive 
indicator of WNT activity in tissue sections 62,93,94.  
 
In the present project experiments were performed with mouse fibroblasts. Expression 
analysis of WNT ligands and WNT/β-catenin pathway components did not suggest WNT 
secretion by fibroblasts, but responsiveness to extracellular paracrine ligand binding on the 
cells. This was further confirmed by an increase of intracellular total β-catenin, the key 
molecule of the signaling pathway, after stimulation with WNT3a, a known inducer of 
WNT/β-catenin signaling. Accumulation of β-catenin is a consequence of dephosphorylation, 
which requires an activated WNT/β-catenin pathway. Significant elevation, of the WNT  
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target molecule and cell cycle regulator Cyclin (CYC) D1 was another finding that indicated 
active WNT signaling. The occurring double band of CYCD1 might be due to 
posttranslational modification, like phosphorylation, which is known to regulate presence, 
localization, and activity of CYCD1 inside the cell 95. In accordance to the protein increase, 
the mRNA level of CycD1 was significantly upregulated after 6 h of stimulation. Pathway 
activation was further confirmed by upregulation of Wisp1, another known target gene 65, 
after 12 h of stimulation with WNT3a. 
Having shown that the WNT/β-catenin signaling pathway can be activated in lung fibroblasts 
by stimulation with WNT3a, the functional relevance thereof was analyzed considering the 
hypothesis of WNT3a having profibrotic effects .  
In particular, changes in proliferation, collagen deposition and marker gene expression after 
stimulation with WNT3a were investigated. 
Concerning proliferation, descriptions of fibroblast phenotypes in pulmonary fibrosis differ in 
literature. High proliferation rates are reported as well as low rates. This diversity may be 
related to different states of the disease, as reviewed by Selman et al. (2001) who assume a 
phenotypic change of fibroblasts in the course of the disease from a first migratory, then 
proliferative and finally synthetically active type 7. Latter exhibit the typical myofibroblast 
characteristics that are contractility and abundant production of extracellular matrix 
components 25. In this phenotype proliferation takes a back seat, what stands in accordance to 
the observation that more advanced fibrosis is associated to low fibroblast proliferation 
rates 96. In the present report fibroblast proliferation was checked after stimulation with 
WNT3a in different serum conditions. Proliferation was not affected after stimulation with 
WNT3a. The lacking proliferation change in 5 % could be referred to an already maximal 
proliferation due to the overabundance of nutrients by the serum. However, in 0.5 % a definite 
capacity for the cells to proliferate is left (compare Figure 14.A). The observation that this is 
not induced by stimulation with WNT3a leads to the conclusion that activated WNT/β-catenin 
signaling in vitro does not have direct proproliferative effects on fibroblasts. In contrast, the 
non canonical ligand WNT5a in a recent study revealed proproliferative effects on 
fibroblasts 97. 
At this point in time the lacking influence on proliferation did not allow excluding the 
contribution of paracrine canonical WNT effects to the synthetic activation of the fibroblasts. 
In fact, there are several reports that claim the synthetic activity of fibroblasts in IPF being 
more emphasized than the proliferation capacity. Raghu et al. (1988) 96 and Hetzel et al. 
(2005) 98 observed higher proliferation rates in normal fibroblasts in response to growth factor  
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stimulation, whereas IPF fibroblasts exhibited enhanced synthetic activity. 
To analyze alteration of the synthetic activity of the fibroblasts by WNT3a or WISP, collagen 
content as a representative ECM component that is expressed and secreted by fibroblasts was 
determined. Before its secretion into the interstitium, procollagen undergoes a large number 
of posttranslational modifications 99. Immunofluorescence staining of stimulated as well as 
unstimulated cells demonstrated that cultured fibroblasts in general produce collagen and 
contain it in their cytoplasm. Staining between the cells indicated secretion of the protein 
reflecting in vivo processes of ECM formation 99. However, stainings did not allow 
quantifying a difference between collagen amount of unstimulated and stimulated fibroblasts. 
Thus, quantitative collagen measurement was performed. The presented data reveal the ability 
of active WNT signaling to increase collagen content in fibroblasts, suggesting an activation 
of de novo collagen synthesis by the ligand. These findings could deliver an explanation for 
the lacking effects on proliferation. Rhudy et al. (1988) reported that fibrillar collagen, which 
is the natural form of type I collagen, acts as a negative regulator on fibroblast 
proliferation 100. 
Actually, for IPF these results indicate a contribution of WNT in a profibrotic manner as de 
novo ECM/collagen synthesis and deposition by fibroblasts represent a characteristic trigger 
of fibrosis 80. This is underlined by the observation that WNT induced collagen increase 
exceeds the one caused by TGF-β1, which was used as a positive control. 
However, it has to be respected that increased collagen production is not necessarily followed 
by increased ECM secretion. Regarding this, it would be interesting to asses ECM/collagen 
secretion of lung fibroblasts after WNT stimulation by supernatant analysis. To confirm the 
results and further quantify the collagen amount, Hydroxyprolinassay could be performed. 
While overexpression of WNT target genes in IPF lungs has already been revealed by 
unbiased microarray screens 64,101,102, the present report aimed to analyze the functional 
relevance of active WNT/β-catenin signaling. Either ECM components or myofibroblast 
marker encoding genes were chosen to be analyzed by quantitative RT-PCR after stimulation 
with WNT3a. Interestingly, for type I collagen α1 (Col1a1) and type I collagen α2 (Col1a2) 
no significant regulations on the mRNA level were observed, while collagen protein was 
significantly increased. 
This discrepancy between the WNT induced increase of total collagen protein amount and the 
unaffected mRNA levels of Col1a1 and Col1a2 could be referred to mRNA upregulation of 
other fibrillar collagen types than the analyzed ones. Furthermore, a significant change in 
collagen amount was observed after 20 h. During this time not necessarily directly WNT  
 
 
5. Discussion 51 
induced pathways do have to lead to different protein patterns inside the fibroblasts. The 
discrepancy between mRNA and protein level suggests more complex ways of regulation 
including crosstalks to other profibrotic pathways or expression of still unknown target genes 
as intermediary effectors. Moreover, the large number of posttranslational modification of 
collagen before being secreted offers contact points for regulation mechanisms. These 
different explanation approaches should be included in further investigations, as well as a 
protein analysis that is able to distinguish between different collagen types.  
Transcription of Fibronectin (Fn), another ECM component that is expressed in interstitial 
fibroblasts and recently has been assigned a causative role in pulmonary fibrosis 103 was not 
significantly regulated, proposing WNT/β-catenin signaling not to be directly contributing to 
this part of the pathogenesis. In contrast, the main known myofibroblast activation marker 
αSma exhibited significant upregulation after 6 h stimulation whereas fiboblast-specific 
protein (Fsp) 1 104 and Vimentin (Vim) were not regulated. This is in accordance with the 
assumption of WNT being causative for a phenotypic switch of inactive fibroblasts to 
activated myofibroblasts as αSma is the most specific marker for this fibroblast phenotype. 
To reveal possible crosstalks to pathways already known to be involved in IPF pathogenesis, 
effects on transcription of Tgf-β1 80,105 and arginase (Arg) 1 and 2 81,106 were analyzed. TGFβ-
1 is known to induce collagen production in fibroblasts 21,80 and a connection between 
WNT/β-catenin pathway and TGF-β has already been reported 107. Additionally, by catalyzing 
L-arginine the arginases provide L-proline that is generated sequentially from L-ornithine and 
L-arginine and forms an important part of the procollagen polypeptide 81. Our analysis did not 
reveal any regulation of either Tgfβ-1 or Arg on the mRNA level, suggesting a different origin 
of collagen increase so far. 
In their study about the functional role and species specific contribution of arginases in 
pulmonary fibrosis, Kitowska et al. (2008) also emphasize the importance of posttranslational 
processing for regulating mechanisms of collagen 81. They showed that TGFβ-1 induces Arg 1 
expression as well as a collagen increase on mRNA and protein level in mouse fibroblasts. 
Whereas Arg inhibition attenuated the TGFβ-1 induced collagen increase on protein level, the 
inhibitory effect did not affect the mRNA level. This discrepancy between collagen mRNA 
and protein level stands in accordance to the observations in the present study. 
After analysing the functional effects of WNT3a on fibroblasts, a similar investigation was 
performed with WNT1-inducible Signaling Protein 1 (WISP1) or CCN4. This member of the 
CCN family of secreted cysteine-rich regulatory proteins 65 was chosen for different reasons: 
WISP1 is encoded by a WNT/β-catenin downstream target gene 69 and thus, an effector of  
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WNT/β-catenin signaling that is involved in pulmonary fibrosis 61,62. Additionally, a role of 
CCN family members as signal transducers in developmental and pathologic processes is 
strongly suggested 66,69-75. In detail, not only the association to WNT signaling suggests a role 
of WISP1 in lung fibrosis, moreover the molecule itself has already been shown to be 
upregulated in IPF lung homogenates 63. In our laboratory, an increased expression of WISP1 
in homogenates and alveolar epithelial cells type II (ATII) was observed in samples of 
experimental lung fibrosis and IPF. Localized next to hyperplastic ATII cells in vivo and vitro 
the protein was shown to have autocrine proproliferative effects on this cell type. 
Furthermore, WISP1 treatment resulted in an increase of profibrotic cytokines like Mmp7 108 
in these cells. Together with the observation that lung fibrosis in vivo could be attenuated by 
inhibition of WISP1 these data suggest a key pathogenic role of this WNT target in initiation 
and perpetuation of IPF. Whereas ATII cells were the cell type that exhibited expression as 
well as autocrine affection by WISP1, in fibroblasts - the key effector cells of the disease - 
enhanced expression of the protein was not observed. In this context we considered 
fibroblasts as possible target cells of paracrine WISP1 binding 66. This suggestion was 
strengthened by the observation that CTGF, another member of the CCN family, has already 
been shown to stimulate fibroblast matrix production and myofibroblast differentiation in a 
paracrine fashion 109. 
Finally, all these findings allowed the hypothesis that WISP1 contributes to IPF pathogenesis 
by having profibrotic effects on lung fibroblasts. Therefore, its functional effects were 
analyzed in the same way as before with WNT3a. 
A recent publication by Colston et al. 73 demonstrated a proproliferative effect of WISP1 on 
cardiac fibroblasts, which suggested a role of the protein in remodeling of myoacardial 
infarction. In contrast to these observations, in the present study no influence on fibroblast 
proliferation was detected. Thus, not just cell type specific but also organ specific 
downstream effects of WISP1 can be proposed. These differences could possibly be explained 
by elucidating still unclear mechanisms of intracellular mechanisms after WISP binding to the 
cell surface considering variable environmental conditions of the cells in different tissues and 
organs. 
To analyze activation of the fibroblasts and the possible influence of WISP1 on ECM 
deposition, localization, and amount of collagen in the cells were determined. 
Immunofluorescence staining of collagen inside the cytoplasm of all cells and also slightly 
beyond indicated general ability of the fibroblasts to produce and secrete collagen, but did not  
allow determining quantitative differences between stimulated and unstimulated fibroblasts.  
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In regard to quantitative measurement of collagen content by Sircol Collagen Assay, 
demonstrated results align with the effects described by Colston et al. (2007) 73. Though, they 
observed a significant collagen increase of cardiac fibroblasts after 72 h, whereas in the 
current study the increase was already discovered after 20 h of stimulation with WISP1.  
The relevance of these possibly profibrotic effects can be emphasized as the increase of 
collagen production of subconfluent fibroblasts was even higher than after treatment with 
TGF-β1, similar to the results of the stimulation experiments with WNT3a.  
In contrast to the results for WNT3a, enhanced collagen synthesis after WISP1 treatment of 
the fibroblasts can be explained by preceding activation of the cells and transcriptional 
upregulation of fibrillar collagens. This can be stated because of increased expression of type 
I collagen α1 (Col1a1) and type I collagen α2 (Col1a2) mRNA after 12 h stimulation with 
WISP1. Whereas other collagen types IV (Col4) and VII (Col7) did not reveal relevant 
upregulation, the expression of the ECM component Fibronectin (Fn) 1 was increased after 
6 h, underlining the capacity of WISP1 to trigger the enhancement of ECM deposition.  
A contribution of WISP1 to the phenotype switch of inactivated fibroblasts to myofibroblasts 
and thereby activation of the cells can be assumed because of transcriptional upregulation of 
the (myo)-fibroblast activation marker αSma and fibroblast-specific protein 1 (Fsp1), which 
was already reported to play a role in epithelial-to-mesenchymal transition (EMT) in tissue 
fibrosis 104.  
Disturbed ECM degradation belongs to pulmonary fibrosis as well as excessive production. 
To reveal possible effects of WISP1 in this subarea, further research projects are necessary. 
However, to touch on this subject, transcriptional regulation of a potentially involved 
molecule was checked: Plasminogen activator inhibitor (PAI) 1 belongs to the plasmin 
system, which plays a crucial role for ECM degradation. By inhibiting plasminogen 
activators, PAI-1 is able to regulate the activation from plasminogen to plasmin. Thereby it 
has the capacity to inhibit plasmin induced ECM degradation or activation of degrading 
molecules respectively 82. Expression of PAI-1 is known to be elevated in experimental 
fibrosis models and pulmonary fibrosis 82. Transcriptional regulation via WISP1 in fibroblasts 
could have delivered information about the involvement of the ligand in ECM degradation. 
Increase of Pai-1 after stimulation would have argued for profibrotic features of WISP1. 
However, no significant upregulation has been observed for the investigated time points. 
Summarizing the presented data a profibrotic role of WISP1 on lung fibroblasts can be stated. 
Increased expression of (myo-) fibroblast activation markers argues for this conclusion as 
well as enhanced collagen production on protein level with according upregulation of type I  
 
 
5. Discussion 54 
collagen on mRNA level. These observations predominantly have to be considered as 
paracrine effects of WISP1 on fibroblasts in IPF as its expression was exclusively enhanced in 
alveolar epithelial cells 77. An autocrine role of the ligand in IPF fibroblasts is rather unlikely 
because in our laboratory we neither detected increased mRNA nor protein expression of 
WISP1 in fibroblasts from experimental lung fibrosis and IPF lungs 77. Therefore, the 
explanation approach that WISP1 is encoded by a WNT responsive gene and thus, could have 
been an intermediary effector for profibrotic WNT effects, takes a back seat. In fact, data 
from the present study suggest WISP1 as a paracrine profibrotic ligand on lung fibroblasts as 
a result from enhanced expression and secretion by hyperplastic ATII cells within the 
progression of IPF. 
 
5.3. Conclusions and future perspectives in regard to IPF 
pathogenesis 
Idiopathic pulmonary fibrosis (IPF) still has the worst prognosis of all idiopathic interstitial 
pneumonias (IIP). Appropriate therapies do not exist yet, which is mostly due to the fact that 
the pathomechanisms of the disease are not completely understood. However, extensive 
research in this issue has revealed WNT/β-catenin signaling including the WNT-target 
molecule WISP1 to be involved in processes leading to progression of fibrosis 36.  
Experiments of this study were performed in order to test the hypothesis that WNT/β-catenin 
signaling can be activated in lung fibroblasts by paracrine binding of WNT ligands and that 
WNT3a and the WNT target molecule WISP1 have profibrotic effects on lung fibroblasts, 
thereby contributing to the impaired crosstalk between ATII cells and fibroblasts during the 
pathogenesis of IPF. Data are received from in vitro experiments with NIH-3T3 mouse 
fibroblasts. To evaluate the relevance of the obtained results in regard to IPF pathogenesis 
further experiments with primary and human cells as well as in vivo experiments are desirable 
and necessary. Nevertheless, the used fibroblast cell line is well established in culture and 
frequently used for basic research indicating reactions of the human system. 
Concerning the question, if WNT/β-catenin signaling can be activated in fibroblasts, it was 
demonstrated that pathway components are expressed constitutively in these cells and target 
genes after stimulation with WNT3a. These observations confirmed that fibroblasts exhibit 
WNT responsiveness. Functional relevance thereof was demonstrated by pointing out 
paracrine effects of WNT3a particularly with regard to a possible profibrotic role. Whereas 
proliferation remained unaffected, a collagen increase on protein level indicated influence of  
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WNT in a profibrotic manner. Furthermore, a contribution of activated WNT/β-catenin 
signaling to the phenotype switch of inactivated fibroblasts to activated myofibroblasts can be 
assumed because of transcriptional upregulation of a fibroblast activation marker. The 
collagen increase on protein level could not be clearly ascribed to upregulation on mRNA 
level. As this discrepancy could not be explained by analysis of potential crosstalk partners or 
molecules possibly involved in posttranslational modification changes, further experiments 
are required to enlighten reasons for the unambiguous collagen increase inside the cells after 
activation of the β-catenin pathway by binding of WNT3a to the cell surface.  
The glycoprotein WISP1, encoded by a WNT target gene, was also analyzed as a paracrine 
ligand with potential profibrotic effects on fibroblasts. Experimental results demonstrate that 
WISP1 leads to fibroblast activation as well as enhanced ECM deposition. Here, a causative 
connection between collagen increase on protein level and upregulation of corresponding 
mRNA can be stated. 
Analysing fibroblast activation markers and collagen production in fibroblasts was mainly 
aimed at elucidating possible effects of WNT3a or WISP1 on one of the key pathogenic 
mechanisms that characterize the fatal course of IPF: extensive ECM deposition by activated 
fibroblasts. However, ECM imbalance during fibrosis not only consists of extensive ECM 
accumulation but also disturbed degradation. Thus, another interesting research focus would 
be to check expression, synthesis and secretion of molecules that are involved into ECM 
degradation like matrixmetalloproteinases (MMP) or tissue inhibitors of metalloproteinases 
(TIMP) 80. These molecules could be influenced during IPF as well as mediators of 
apoptosis 72. As this part was not the focus of the current study, on transcriptional and protein 
level further investigation is possible and required to reveal the functional effects of both 
ligands entirely.  
From the results of the present study can be concluded that WNT3a and WISP1 act in a 
paracrine fashion as profibrotic mediators on fibroblasts in vitro. Together with current 
research results about IPF and WNT signaling this detection strongly suggests WNT/β-
catenin signaling and its effectors to be functional in fibroblasts during the pathogenesis of 
IPF. Inhibiting WNT/β-catenin signal transduction or antagonizing its downstream effectors 
could possibly prevent fibroblasts from advancing the diseases´ progression. Thus, elucidating 
the downstream mechanisms and the effects of WNT and WISP on fibroblasts in vivo and in 
the human system is a worthwhile aim for further investigation.  
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6.1 Primer sequences and amplicon sizes 
Gene Accession  Sequences (5´  3´) Length Amplicon 
for gga acc cag aga gag cat ga 20bp 
Arg1 NM007482 
rev ttt ttc cag cag acc agc tt 20bp 
132bp 
for acc agg aac tgg ctg aag tg 20bp 
Arg2 NM009705 
rev tga gca tca acc cag atg ac 20bp 
141bp 
for tca aga gag caa gct cat cat tct  24bp 
β-Cat NM007614 
rev cac ctt cag cac tct tgt g 22bp 
115bp 
for cca aga aga cat ccc tga agt ca 23bp 
Col1a1 NM007742 
rev tgc acg  tca tcg cac aca 18bp 
128bp 
for agc ttt gtg gat acg cgg act 21bp 
Col1a2 NM007743 
rev tcg tac tga tcc cga ttg ca 20bp 
86bp 
for ctt ctg cga ttt cgg ctc c 19p 
Ctgf NM010217 
rev tgc ttt gga agg act cac cg 20bp 
115bp 
for atg cca gag gcg gat gag a 19bp 
CycD1 NM007631 
rev atg gag ggt ggg ttg gaa at 20bp 
98bp 
for gtg tag cac aac ttc caa tta cga a 25bp 
Fn NM010233 
rev gga att tcc gcc tcg agt ct 20bp 
 
90bp 
for agg agc tac tga cca ggg agc t 22bp  
Fsp1 
 
NM011311 rev tca ttg tcc ctg ttg ctg tcc 21bp 
 
102bp 
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Gene Accession  Sequences (5´  3´) Length Amplicon 
for aaa cag cac agg ttc tgc aaa a 22bp 
Fzd1 NM021457 
rev tgg gcc ctc tcg ttc ctt  18bp 
58bp 
for tcc atc tgg tgg gtg att ctg 21bp 
Fzd2 NM020510 
rev ctc gtg gcc cca ctt cat t 19bp 
66bp 
for gcc tat agc gag tgt tca aaa ctc a 25bp 
Fzd3 NM021458 
rev tgg aaa cct act gca ctc cat atc t 25bp 
78bp 
for gcc cca gaa cga cca caa 18bp 
Fzd4 NM008055 
rev ggg caa ggg aac ctc ttc at 20bp 
64bp 
for ccc acc gca cgt ttt cc 17bp 
Fzd5 NM02272 
rev gct ttt cat ttc gct tgt tat c 25bp 
63bp 
for gtt cta ccc tgt cgg aaa ttg tg 23bp 
Fzd6 NM008056 
rev gtg gat gag aag tta cag gaa cag tgt 27bp 
146bp 
for gcc agg tgg atg gtg acc ta 20bp 
Fzd7 NM008057 
rev ccg caa tgc atc cac act ag 20bp 
68bp 
for gca agg agg ccc aac taa gac 21bp 
Fzd8 NM008058 
rev gag gcc caa gcg gat ca 17bp 
58bp 
for ttt gag ctg gta ccc tag gat ga 23bp 
Gsk3β NM019827 
rev ttc ttc gct ttc cga tgc a 19bp 
75bp 
for ggc ggc gtt gga cag at 17bp 
Lef1 NM010703 
rev cac ccg tga tgg gat aaa cag 21bp 
67bp 
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Gene Accession  Sequences (5´  3´) Length Amplicon 
for caa cgt gga cgt gtt tta ttc ttc 24 bp 
LRP5 NM008513 
rev cag cga ctg gtg ctg tag tca 21 bp 
138 bp 
for cca ttc ctc tca ctg gtg tca a 22 bp 
LRP6 NM008514 
rev gcc aaa ctc tac cac atg ttc ca  23 bp 
146 bp 
for gtc ttt ccg acc aag agc ag 20 bp 
Pai1 NM008871 
rev gac aaa ggc tgt gga gga ag 20 bp 
104 bp 
for atg tcc ggt aac ggc ggc 18 bp 
Pbgd NM135511 
rev ggt aca agg ctt tca cga 22 bp 
121 bp 
for gct ggt gat gat gct ccc a 19 bp 
αSma NM007392 
rev gcc cat tcc aac cat tac tcc 21 bp 
80 bp 
for agg tca ccc gcg tgc taa t 19 bp 
Tgfβ-1 NM011577 
rev ggc act gct tcc cga atg t 19  bp 
115 bp 
for caa atg gca att ccg aaa cc 20 bp 
Wnt1 NM021279 
rev gat tgc gaa gat gaa cgc tg 20 bp 
111 bp 
for gca cca ccg tga gca aca 18 bp 
Wnt3a NM009522 
rev ggg tgg ctt tgt cca gaa ca 20 bp 
56 bp 
for tgg gac cgt tgg aat tgc  18 bp 
Wnt8b NM011720 
rev ccg gtt agc gct tcg aag t  19 bp 
72 bp 
for atg agt gcc agc atc agt tcc 21 bp 
W10a NM009518 
rev gcg tag gcg aaa gca ctc tc 20 bp 
123 bp 
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Gene Accession  Sequences (5´  3´) Length Amplicon 
for tgg gac gcc agg tgg taa 18 bp 
Wnt10b NM011718 
rev ctg acg ttc cat ggc att tg 20 bp 
60 bp 
for ccc cca act acc tgc ttg ac 20 bp 
Wnt11 NM009519 
rev ggc cga cag ggc ata cac 18 bp 
68 bp 
  
Table 3. Primer sequences and amplicon sizes. 
The primer sets work under identical real-time PCR cycling conditions with similar efficiencies to obtain 
simultaneous amplification in the same run. Sequences were taken from GeneBank, Accession numbers are 
given. 
 
6.2 Dissociation curves 
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Figure 14. Dissociation curves 
Primer sets of WNT/β-catenin pathway components 
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